WO2010131675A1 - 水酸基を有する生理活性物質の高分子結合体 - Google Patents
水酸基を有する生理活性物質の高分子結合体 Download PDFInfo
- Publication number
- WO2010131675A1 WO2010131675A1 PCT/JP2010/058034 JP2010058034W WO2010131675A1 WO 2010131675 A1 WO2010131675 A1 WO 2010131675A1 JP 2010058034 W JP2010058034 W JP 2010058034W WO 2010131675 A1 WO2010131675 A1 WO 2010131675A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- polymer conjugate
- compound
- physiologically active
- general formula
- Prior art date
Links
- 0 C**(*(*)C(O*)=O)C(NO*)=O Chemical compound C**(*(*)C(O*)=O)C(NO*)=O 0.000 description 2
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
- C08G69/02—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids
- C08G69/08—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids derived from amino-carboxylic acids
- C08G69/10—Alpha-amino-carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
- C08G69/40—Polyamides containing oxygen in the form of ether groups
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
- C08G69/48—Polymers modified by chemical after-treatment
Definitions
- the present invention provides a highly active bioactive substance in which a bioactive substance having a hydroxyl group is bonded to a side chain in a block copolymer of a polyethylene glycol structural moiety and a polymer having two or more carboxy groups via a specific linker.
- the present invention relates to a molecular conjugate and its use.
- Physiologically active substances such as anticancer agents and anti-inflammatory agents, particularly polymer conjugates obtained by binding the physiologically active substances that are hardly soluble in water to a polymer carrier, the in vivo pharmacokinetics and water solubility of the physiologically active substance itself It has been studied with the hope of improving its effectiveness and effectiveness.
- block copolymers in which a hydrophilic polymer and a hydrophobic polymer are bonded to each other are supported by forming a micelle with a hydrophobic polymer carrying a physiologically active substance as the inner shell and covering the surface with the hydrophilic polymer. Even if the amount is increased, the water solubility of the whole polymer can be maintained.
- Patent Document 1 describes a compound in which a drug is bound to a block copolymer of polyethylene glycol and polyaspartic acid, which forms micelles and exhibits water solubility, without using a linker
- Patent Document 2 discloses polyethylene glycols and A high molecular derivative of camptothecins in which a side chain carboxy group of a block copolymer with polyglutamic acid and a phenolic hydroxyl group of camptothecins are ester-bonded is described.
- Patent Document 3 describes a compound in which a side chain carboxy group of a block copolymer of polyethylene glycols and polyaspartic acid is bonded to an alcoholic hydroxyl group of a taxane, and succinic acid constituting the polyaspartic acid chain. It is described that the monoamide structure part forms an imide and the ester bond is cleaved to release taxanes.
- Patent Document 4 describes a compound bound to podophyllotoxins
- Patent Document 5 describes a compound bound to combretastatin.
- Patent Document 1 describes doxorubicin as a physiologically active substance.
- a block copolymer and doxorubicin are directly bonded by an amide bond.
- the amide bond is a chemically stable binding mode, and the release of doxorubicin by in vivo hydrolysis is considered to be extremely slow, and the drug efficacy of the polymer conjugate is questionable.
- the polymer conjugate of camptothecins described in Patent Document 2 forms an ester bond in which a physiologically active substance is easily dissociated by bonding a highly reactive phenolic hydroxyl group and a carboxy group of polyglutamic acid. It is characterized by that.
- the polymer conjugate of a cytidine antimetabolite described in Patent Document 6 is a bond in which a physiologically active substance is easily dissociated by binding a highly reactive aromatic amino group to a carboxy group of polyglutamic acid. It is characterized by forming. Accordingly, it is not easy to release a sufficient amount of the physiologically active substance from a polymer conjugate obtained by directly binding a physiologically active substance having a low-reactive alcoholic hydroxyl group or the like to polyglutamic acid.
- Patent Documents 3, 4 and 5 are polymer conjugates of physiologically active substances having alcoholic hydroxyl groups or phenolic hydroxyl groups with low reactivity, they have a succinic acid monoamide structure moiety in the main chain. This makes it possible to release a sufficient amount of a physiologically active substance.
- the present inventors have made a block copolymer of a polyethylene glycol structural moiety and a polymer having two or more carboxy groups, in particular, a side in a polyethylene glycol-polyglutamic acid block copolymer.
- a compound in which a physiologically active substance having a hydroxyl group is ester-bonded to a chain via a specific linker having a succinic acid monoamide structure, and a physiologically active substance is directly bonded to a side chain of a polyethylene glycol-polyaspartic acid block copolymer It has been found that a higher therapeutic effect may be exhibited, and furthermore, by appropriately selecting an amine component that is a component of the linker, it is possible to adjust the release rate suitable for the bound physiologically active substance.
- the present invention has been completed.
- the present invention relates to the following (1) to (25).
- At least one of the side chain carboxy groups of a block copolymer of a polyethylene glycol structural moiety and a polymer having two or more carboxy groups has the general formula (I) or the general formula (II).
- R 8 and R 9 each independently represents a hydrogen atom or a (C1 to C6) alkyl group optionally having substituent (s), and R 10 may have a hydrogen atom or substituent (s).
- a good (C1-C40) alkyl group, an optionally substituted (C1-C40) aralkyl group, an optionally substituted aromatic group, a carboxy-protected amino acid residue or substitution represents a sugar residue that may have a group
- CX-CY represents CH—CH or C ⁇ C (double bond)
- A represents one or more of the above-mentioned one or more physiologically active substances having one or more hydroxyl groups.
- a polymer conjugate of a physiologically active substance in which the substituent represented by the above formula is a residue obtained by removing any one of the hydroxyl groups.
- R 1 represents a hydrogen atom or a (C1 to C6) alkyl group
- R 2 represents a bonding group
- R 3 represents a hydrogen atom or a (C1 to C6) acyl group
- R 4 represents general formula (I) or general formula (II)
- R 5 represents the general formula (IV) or the general formula (V).
- R 8 , R 9 , R 10 and CX-CY have the same meaning as described above, and R 11 has a hydroxyl group, an aromatic amino group which may have a substituent, and a substituent.
- One or more substituents selected from the group consisting of di (C1-C30) alkylamino group, carboxy-protected amino acid, and NR 12 CONHR 13 , which may be the same, and R 12 and R 13 are the same or different (C3-C6) may be substituted with a cyclic alkyl group or a tertiary amino group (C1-C5) represents an alkyl group].
- R 6 represents the general formula (VI)
- R 7 is a (C1-C30) alkoxy group, a (C1-C30) aralkyloxy group, a (C1-C30) alkylamino group, a di (C1-C30) alkylamino group, a carboxy-protected amino acid, and an NR 12 CONHR
- R 12 and R 13 may be the same or different (C3 to C6) and may be substituted with a cyclic alkyl group or a tertiary amino group (C1 to C5).
- R 1 is a (C1 to C3) alkyl group
- R 2 is a (C2 to C6) alkylene group
- R 3 is a (C1 to C3) acyl group
- b is an integer of 100 to 300
- I is an integer of 1 to 90
- j, k, m, n are each an integer of 0 to 90
- i + j + k + m + n is an integer of 6 to 90.
- R 1 is a methyl group
- R 2 is a trimethylene group
- R 3 is acetyl group
- R 4 R 5 and both hydrogen atoms
- R 8 R 9 is in the R 6
- CX-CY is in CH-CH
- physiologically active substance according to any one of (1) to (6), wherein the physiologically active substance having one or more hydroxyl groups is an analgesic, a hair-restoring agent, or a myocardial protective agent due to a myocardial infarction size reduction effect.
- Polymer conjugates are provided.
- a pharmaceutical comprising as an active ingredient a polymer conjugate of the physiologically active substance according to any one of (1) to (22).
- An anticancer agent comprising a polymer conjugate of the physiologically active substance according to any one of (7) to (17) as an active ingredient.
- An anti-inflammatory agent comprising the polymer conjugate of the physiologically active substance according to (18) or (19) as an active ingredient.
- the polymer conjugate of the physiologically active substance of the present invention is a compound in which a physiologically active substance having a hydroxyl group is bonded to the side chain of a block copolymer of polyethylene glycol and polyglutamic acid via a specific linker. Can exert biological effects.
- the polymer conjugate of the present invention can release a physiologically active substance under physiological conditions without depending on a hydrolase in a living body, it is effective biologically without being affected by individual differences. The effect is expected. Furthermore, it is possible to adjust the release rate suitable for the physiologically active substance bound by appropriately selecting an amine component that is a constituent element of the linker.
- the polymer conjugate of the physiologically active substance of the present invention contains at least one of the side chain carboxy groups of a block copolymer of a polyethylene glycol structural moiety and a polymer having two or more carboxy groups, the above general formula (I) Alternatively, general formula (II) [wherein R 8 and R 9 each independently represents a hydrogen atom or an optionally substituted (C1 to C6) alkyl group, and R 10 represents a hydrogen atom or a substituent. (C1-C40) alkyl group which may have a substituent, (C1-C40) aralkyl group which may have a substituent, an aromatic group which may have a substituent, and a carboxy group are protected.
- CX-CY represents CH—CH or C ⁇ C (double bond)
- A represents a physiologically active substance having one or more hydroxyl groups
- the substituent represented by [denotes a residue excluding any one of the above hydroxyl groups] has an amide bond.
- a polymer having two or more carboxy groups in a block copolymer of a polyethylene glycol structural moiety and a polymer having two or more carboxy groups has a carboxy group in the side chain.
- a polymer formed by polymerizing a low molecular weight monomer or a polymer obtained by introducing a carboxy group into a polymer of a low molecular weight monomer having a functional group other than a carboxy group such as a hydroxyl group using halogenoacetic acid may be used.
- polymer examples include polyglutamic acid, polyaspartic acid, polyserine, polycysteine, polytyrosine, polylysine, polymalic acid, dextran or a partially oxidized product thereof, polyuronic acid, and the like.
- polyacidic amino acids such as polyglutamic acid and polyaspartic acid are preferable.
- a block copolymer of a polyethylene glycol structural part and polyglutamic acid is particularly preferable.
- R 8 and R 9 each independently have a hydrogen atom or a substituent.
- (C1 to C6) alkyl groups may be mentioned, and examples of the substituent include a methyl group, an ethyl group, and an isopropyl group.
- R 8 and R 9 are particularly preferably both hydrogen atoms.
- R 10 may have a hydrogen atom, an optionally substituted (C1 to C40) alkyl group, an optionally substituted (C1 to C40) aralkyl group, or an optionally substituted group.
- An aromatic group, an amino acid residue in which a carboxy group is protected, or a sugar residue that may have a substituent may be mentioned.
- Examples of the (C1 to C40) alkyl group in the optionally substituted (C1 to C40) alkyl group include a methyl group, an ethyl group, an n-propyl group, an isopropyl group, an n-butyl group, an s- Examples include a butyl group, an isobutyl group, an n-pentyl group, an n-hexyl group, and an n-stearyl group.
- Examples of the substituent include a phenyl group, a naphthyl group, a phenylmethyl group, a methoxy group, an ethoxy group, and dimethyl group. An amino group etc. are mentioned.
- Examples of the (C1 to C40) aralkyl group in the (C1 to C40) aralkyl group which may have a substituent include a benzyl group, a naphthylmethyl group, a phenethyl group, a 4-phenylbutyl group, and the like.
- Examples of the group include a methyl group, an ethyl group, a nitro group, a chlorine atom, a bromine atom, and a dimethylamino group.
- aromatic group which may have a substituent examples include substituents derived from aniline, nitroaniline, chloroaniline, aminofluorobenzonitrile, aminonaphthalene, aminoflavone, aminofluorene and the like.
- substitution position of the substituent is not particularly limited as long as substitution is possible, and the number of substituents is not particularly limited.
- amino acid of the amino acid residue in which the carboxy group is protected examples include amino acids in which the carboxy group used in normal peptide synthesis is protected, and a compound in which the carboxy group of the amino acid is protected by an ester or an amide is desirable.
- Examples of the sugar of the sugar residue that may have a substituent include glucosamine, galactosamine, mannosamine and the like, and examples of the substituent include an acetyl group, a pivaloyl group, a benzyl group, and a methyl group.
- the sugar may be D-form, L-form, or a mixture thereof. Further, the position and number of substituents are not limited as long as they are possible.
- the CX-CY in the general formula (I) or the general formula (II) serving as a linker in the polymer conjugate of the physiologically active substance of the present invention is not limited as long as the linker moiety can form a cyclic imide intermediate, and CH—CH or C ⁇ C (double bond), and examples thereof include succinic acid monoamide derivatives and maleic acid monoamide derivatives.
- the physiologically active substance of the physiologically active substance residue having a hydroxyl group ester-linked to the linker is not particularly limited, but has a phenolic hydroxyl group, a primary hydroxyl group or a secondary hydroxyl group
- a physiologically active substance is preferred.
- the residue of a physiologically active substance is a part of a compound obtained by removing a hydroxyl group bonded to a linker from a physiologically active substance having one or more hydroxyl groups.
- the substitution position of the phenolic hydroxyl group, primary hydroxyl group or secondary hydroxyl group is not particularly limited, and may be single or different in one molecule, and may be the same or different between molecules.
- these hydroxyl groups may be bonded to the same or different block copolymers, and these are also included in the present invention.
- physiologically active substances examples include taxanes such as paclitaxel and docetaxel as anticancer agents, podophyllotoxins such as podophyllotoxin, etoposide or teniposide, combretastatins such as combretastatin A1, combretastatin A4, etc. And other camptothecins and their analogs, such as gemcitabine, capecitabine, capecitabine, doxyfluridine, cytarabine, 3′-ethynylcytidine, etc. of nucleic acids, doxorubicin, amrubicin, aclacinomycin etc.
- steroids having a phenolic hydroxyl group or an alcoholic hydroxyl group, such as prednisolone, methylprednisolone, dexamethasone, betamethasone, clobetasol, diflorazone, diflucortron.
- adenosine can be cited as a cardioplegic agent by hair tonic or myocardial infarction size reduction effect.
- the general formula (III) [wherein R 1 represents a hydrogen atom or a (C1-C6) alkyl group, R 2 represents a linking group, and R 3 represents A hydrogen atom or (C1-C6) acyl group, R 4 represents a substituent represented by the above general formula (I) or general formula (II) [wherein R 8 , R 9 , R 10 , CX-CY, A has the same meaning as described above] R 5 represents the above general formula (IV) or general formula (V) [wherein R 8 , R 9 , R 10 and CX-CY have the same meaning as described above, and R 11 has a hydroxyl group and a substituent.
- An aromatic amino group which may have a substituent, an optionally substituted (C1 to C30) alkoxy group, an optionally substituted (C1 to C30) an aralkyloxy group and a substituent.
- R 12 and R 13 may be the same or different (C3-C6) and may be substituted with a cyclic alkyl group or a tertiary amino group (C1-C5) represents an alkyl group].
- R 6 represents a substituent represented by the above general formula (VI) [wherein R 8 , R 9 , R 10 and CX-CY have the same meaning as described above], R 7 is a (C1-C30) alkoxy group, a (C1-C30) aralkyloxy group, a (C1-C30) alkylamino group, a di (C1-C30) alkylamino group, a carboxy-protected amino acid, and an NR 12 CONHR And R 12 and R 13 may be the same or different (C3 to C6) and may be substituted with a cyclic alkyl group or a tertiary amino group (C1 to C5).
- b represents an integer of 5 to 11,500
- i represents an integer of 1 to 200
- n each represents an integer of 0 to 200
- i + j + k + m + n represents an integer of 2 to 200
- the compound represented by] is preferable.
- Examples of the (C1 to C6) alkyl group in R 1 in the general formula (III) include a linear or branched alkyl group of (C1 to C6), preferably a (C1 to C4) alkyl group.
- Examples thereof include a methyl group, an ethyl group, an n-propyl group, an n-butyl group and the like, and among them, a methyl group is particularly preferable.
- a (C2 to C6) alkylene group is preferable, and examples thereof include an ethylene group, a trimethylene group, a tetramethylene group, and the like, and a trimethylene group is particularly preferable.
- the (C1-C6) acyl group in R 3 in the general formula (III) is not particularly limited, and preferably a (C1-C3) acyl group, for example, a formyl group, an acetyl group, a propionyl group, etc. Among them, an acetyl group is particularly preferable.
- R 8 as the R 8, R 9 in the general formula (I) or formula (II) for R 4 in formula (III), the general formula (I) or formula (II), R 9
- a preferable group is a hydrogen atom similarly.
- R 10 in general formula (I) or general formula (II) in R 4 in general formula (III) include the same groups as R 10 in general formula (I) or general formula (II) described above. .
- physiologically active substance residue A in general formula (I) or general formula (II) in R 4 in general formula (III) the same physiology as A in general formula (I) or general formula (II) described above is used. Active substance residues are mentioned.
- R 8 , R 9 , R 10 , and CX—CY in R 5 in general formula (III) in general formula (IV) or general formula (V) are the above general formula (I) or general formula (II).
- R 8 , R 9 , R 10 , and CX-CY are the same groups.
- an anilino group As the aromatic amino group optionally having a substituent as R 11 in the general formula (IV) or the general formula (V) in R 5 in the general formula (III), an anilino group, a naphthylamino group, Examples include a pyridylamino group, an amino group of adenosine, an amino group of cytidine, an amino group of nucleic acid, and the like.
- R 5 in general formula (III) may have a substituent as R 11 in general formula (IV) or general formula (V) (C1 to C30) (C1 to C30) alkoxy in the alkoxy group
- the group include a linear or branched (C1 to C30) alkoxy group, and a linear or branched (C1 to C10) alkoxy group is preferable.
- a methoxy group, an ethoxy group, an n-propoxy group, An i-propoxy group, an n-butoxy group, a t-butoxy group, and the like can be given.
- the substituent include a phenyl group, a naphthyl group, a phenylmethyl group, a methoxy group, an ethoxy group, and a dimethylamino group.
- Examples of the (C1 to C30) aralkyloxy group in the optionally substituted (C1 to C30) aralkyloxy group include a linear or branched (C1 to C30) aralkyloxy group.
- a branched (C1 to C12) aralkyloxy group is preferable, and examples thereof include a benzyloxy group and a 4-phenylbutoxy group.
- Examples of the substituent include a methyl group, an ethyl group, a nitro group, a chloro group, and a bromo group. Group, dimethylamino group and the like.
- the (C1 to C30) alkylamino group or di (C1 to C30) alkylamino group in the (C1 to C30) alkylamino group or di (C1 to C30) alkylamino group which may have a substituent includes Examples thereof include a linear or branched (C1 to C30) alkylamino group or a di (C1 to C30) alkylamino group, and include a linear or branched (C1 to C20) alkylamino group or di (C1 to C20) alkylamino.
- Group is preferred, for example, methylamino group, ethylamino group, n-propylamino group, i-propylamino group, n-butylamino group, t-butylamino group, dimethylamino group, diethylamino group, di (n-butyl) ) Amino group and the like, and examples of the substituent include phenyl group, naphthyl group, phenylmethyl group, methoxy group, ethoxy group, di Chiruamino group, and the like.
- amino acid in which the carboxy group is protected examples include the same amino acids as the amino acid in which the carboxy group in R 10 of the above general formula (I) or general formula (II) is protected, and preferred amino acids are also the same.
- R 12 and R 13 may be the same or different (C3 to C6)
- the cyclic alkyl group or the (C1-C5) alkyl group which may be substituted with a tertiary amino group is not particularly limited.
- a cyclohexylaminocarbonylcyclohexylamino group, an isopropylaminocarbonylisopropylamino group and the like are preferable. .
- the (C1-C30) alkoxy group, (C1-C30) aralkyloxy group, (C1-C30) alkylamino group, di (C1-C30) alkylamino group in R 7 in the general formula (III) are represented by the general formula each group can be mentioned that the as R 11 in the general formula (IV) or general formula (V) in R 5 in (III), it is also preferred group.
- the carboxy group is protected amino, the to which the amino acid is mentioned as R 11 in the general formula (IV) or general formula (V) in R 5 in the general formula (III).
- NR 12 CONHR 13 [R 12 , R 13 may be the same or different (C3-C6) is a cyclic alkyl group or a tertiary amino group (C1-C5) is an alkyl group] formula (III) in the general formula (IV) or the general formula a group are wherein the (V) R 11 in mentioned in R 5 a, is the same preferable groups.
- the total number of glutamic acids in the polymer conjugate of the physiologically active substance represented by the general formula (III) of the present invention is represented by i + j + k + m + n, about 3 to 200, preferably about 6 to 90, The number is preferably 6 to 60, and more preferably 13 to 40.
- the ratio of the number (i) of glutamate bound to the physiologically active substance to the total number of glutamate (i + j + k + m + n) is 1 to 100%, preferably 3 to 100%, and more preferably 4 to 100%. Further, the glutamic acid number (i) is 1 to 200, preferably about 1 to 90, particularly preferably about 2 to 60.
- the constituent order of the glutamic acid structure in the polymer conjugate of the physiologically active substance represented by the general formula (III) is not limited in the order of binding, and may be a block type or a random type.
- b is an integer of about 5 to 11,500, preferably an integer of about 8 to 2300, and more preferably an integer of about 100 to 300.
- the molecular weight of the polyethylene glycol structural moiety of the general formula (III) is about 300 to 500,000, preferably about 500 to 100,000, and more preferably about 1,000 to 50,000.
- the molecular weight of the bioactive substance polymer conjugate of the present invention is about 500 to 600,000, preferably about 600 to 110,000, and more preferably about 1100 to 80,000.
- the molecular weight in this invention is the weight average molecular weight measured by GPC method.
- the polymer conjugate of the physiologically active substance of the present invention may form a micelle having a polyethylene glycol structure portion as an outer shell in water and a hydrophobic polymer to which a physiologically active substance is bonded via a linker as an inner shell. Good.
- the production of the polymer conjugate of the physiologically active substance of the present invention particularly protects a carboxy group having a side chain carboxy group of a block copolymer of a polyethylene glycol structural part and a polyglutamic acid and, for example, an amino group serving as a linker part.
- the succinic acid monoamide derivative or the fumaric acid monoamide derivative having an amino group and protecting the carboxy group is amide-bonded in an organic solvent using a dehydration condensing agent, and the protective group is deprotected to form a carboxy group and a hydroxyl group. It is characterized in that it is ester-bonded with a hydroxyl group of a physiologically active substance having an organic solvent using a dehydrating condensing agent.
- aprotic polar solvent such as N, N-dimethylformamide (DMF), 1,3-dimethyl-2-imidazolidinone (DMI), N-methylpyrrolidone (NMP) Dicyclohexylcarbodiimide (DCC), diisopropylcarbodiimide (DIPC), 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide (WSC) hydrochloride, 1-ethoxycarbonyl-2- Ethoxy-1,2-dihi
- a dehydrating condensing agent such as loxyquinolinone (EEDQ)
- EEDQ loxyquinolinone
- a reaction aid such as N, N-dimethylaminopyridine (DMAP) or 1-hydroxy-1H-benzotriazole (HOBt) may be used.
- DMAP N, N-dimethylaminopyridine
- HOBt 1-hydroxy-1H-benzotriazole
- NR 12 CONHR 13 in R 7 or R 11 can also be obtained by a reaction using the above carbodiimides as a condensing agent.
- a succinic acid monoamide derivative is subjected to a dehydration condensation reaction to activate the remaining carboxy group, wherein (C1-C30) alkoxy group, (C1-C30) aralkyloxy group, (C1-C30) alkylamino group, di (C1 -C30)
- An amino acid or the like in which an alkylamino group or carboxy group is protected may be introduced, and then reacted with a physiologically active substance having a hydroxyl group in the same manner as described above.
- the physiologically active substance having a hydroxyl group has another functional group that reacts with a carboxy group
- the functional group may be protected as necessary and deprotected at an appropriate stage after the condensation reaction.
- the method for producing the polymer conjugate of the physiologically active substance of the present invention is not limited to these.
- the polymer conjugate of the physiologically active substance of the present invention can be used as a medicine for treating a disease corresponding to the medicinal effect of the carried physiologically active substance.
- anticancer agents and anti-inflammatory agents can be used in commonly used dosage forms such as injections, tablets and powders.
- Pharmaceutically acceptable carriers commonly used for formulation such as binders, lubricants, disintegrants, solvents, excipients, solubilizers, dispersants, stabilizers, suspending agents, Preservatives, soothing agents, pigments, fragrances and the like can be used.
- the polymer conjugate of the physiologically active substance of the present invention is preferably used as an injection.
- water, physiological saline, 5% glucose or mannitol solution, water-soluble organic solvent (for example, glycerol, ethanol, dimethyl sulfoxide) N-methylpyrrolidone, polyethylene glycol, cremophor and the like, and a mixture thereof) and a mixture of water and the water-soluble organic solvent are used.
- the dosage of the polymer conjugate of the physiologically active substance of the present invention can be naturally changed depending on the characteristics of the physiologically active substance, the sex, age, physiological state, pathological condition, etc. of the patient, but parenterally, usually an adult
- the active ingredient is administered in an amount of 0.01 to 500 mg / m 2 , preferably 0.1 to 250 mg / m 2 per day.
- Administration by injection is performed in veins, arteries, affected areas (tumor areas) and the like.
- Synthesis Example 1 Synthesis of Compound 1 (Glycine (4-phenyl-1-butanol) ester) 1.0 g of glycine hydrochloride (manufactured by Wako Pure Chemical Industries) and 6.7 g of 4-phenyl-1-butanol (manufactured by Tokyo Chemical Industry) After suspension in 5 ml of dioxane, 5 ml of 4N-hydrochloric acid / dioxane was added, and the mixture was stirred at room temperature for 3 days. The insoluble material was filtered off and washed with 5 ml of dioxane.
- Synthesis Example 3 Synthesis of compound 3 (aspartic acid ⁇ -benzyl ester-glycine methyl ester) N- (tert-butoxycarbonyl) aspartic acid ⁇ -benzyl ester (produced by Kokusan Kagaku) 0.97 g and glycine methyl ester hydrochloride (made in Japan) Chemical (0.38 g) was dissolved in 19 ml of DMF, 0.42 ml of triethylamine, 0.51 g of HOBt, and 0.63 g of WSC hydrochloride were added and stirred overnight at room temperature.
- the reaction solution was extracted with ethyl acetate and washed with cold water, dilute hydrochloric acid, saturated aqueous sodium hydrogen carbonate solution and saturated brine in this order. Under reduced pressure, ethyl acetate was distilled off and vacuum-dried to obtain 1.2 g of a solid. The obtained solid was dissolved in 15 ml of ethyl acetate, 15 ml of 4N HCl / ethyl acetate was added, and the mixture was stirred at room temperature for 1 hour. 120 ml of diethyl ether was added to the reaction solution, and after stirring at room temperature for 2 hours, the solvent was removed by a gradient method, and then the solid was washed with diethyl ether.
- Synthesis Example 6 Synthesis of compound 6 (aspartic acid ⁇ -benzyl ester-glycine (4-phenyl-1-butanol) ester) N- (tert-butoxycarbonyl) aspartic acid ⁇ -benzyl ester (produced by Kokusan Kagaku) 1.3 g Then, 0.97 g of the hydrochloride of Compound 1 obtained in Synthesis Example 1 was dissolved in 23 ml of DMF, 0.56 ml of triethylamine, 0.73 g of HOBt and 0.84 g of WSC hydrochloride were added, and the mixture was stirred overnight at room temperature. Next, 2.0 g of a solid was obtained by the same operation as in Example 3.
- the obtained precipitate was dissolved in 44 ml of acetonitrile and 11 ml of water at 5 ° C., passed through an ion exchange resin (Dow Chemical Dowex 50 (H + ), 5 ml), and acetonitrile / water (5/1 ( v / v) and 15 ml). 75 ml of water was added to the obtained elution fraction, acetonitrile was distilled off under reduced pressure, and then freeze-dried to obtain Compound 8 (2.71 g).
- the content of aspartic acid ⁇ -benzyl ester-glycine methyl ester bound to compound 8 was determined by adding 2N-sodium hydroxide aqueous solution to compound 8 and stirring at 40 ° C. for 1 hour, and then releasing benzyl alcohol by HPLC (high performance liquid chromatography). ) And calculated from the amount of benzyl alcohol obtained from a calibration curve obtained with commercially available benzyl alcohol.
- the content of bound aspartic acid ⁇ -benzyl ester-glycine methyl ester was 28.3% (w / w), and the ratio of j to the total glutamic acid (i + j + k + m + n) was 93%.
- the carbonyl group in the side chain of the remaining glutamic acid has an isopropylaminocarbonylisopropylamide group or a hydroxyl group bonded thereto.
- the content of aspartic acid ⁇ -benzyl ester-phenylalanine methyl ester bound to compound 9 was calculated from the amount of benzyl alcohol obtained in the same manner as in compound 8. As a result, the content of bound aspartic acid ⁇ -benzyl ester-phenylalanine methyl ester was 34.0% (w / w), and the ratio of j to the total glutamic acid (i + j + k + m + n) was 93%.
- An isopropylaminocarbonylisopropylamide group or a hydroxyl group is bonded to the remaining side chain of glutamic acid.
- the precipitate obtained by the same operation as the compound 8 was dissolved in 70 ml of acetonitrile and 20 ml of water at 5 ° C., and then dissolved in an ion exchange resin (Dow Chemical Dowex 50 (H + ), 10 ml).
- the column was passed through and eluted with acetonitrile / water (5/1 (v / v), 30 ml). 130 ml of water was added to the obtained elution fraction, acetonitrile was distilled off under reduced pressure, and then freeze-dried to obtain Compound 10 (4.26 g).
- the content of aspartic acid ⁇ -benzyl ester-leucine methyl ester bound to compound 10 was calculated from the amount of benzyl alcohol obtained in the same manner as in compound 8. As a result, the content of bound aspartic acid ⁇ -benzyl ester-leucine methyl ester was 28.9% (w / w), and the ratio of j to the total glutamic acid (i + j + k + m + n) was 81%.
- An isopropylaminocarbonylisopropylamide group or a hydroxyl group is bonded to the remaining side chain of glutamic acid.
- the precipitate obtained by the same operation as the compound 8 was dissolved in 70 ml of acetonitrile and 20 ml of water at 5 ° C., and then dissolved in an ion exchange resin (Dow Chemical Dowex 50 (H + ), 10 ml).
- the column was passed through and eluted with acetonitrile / water (5/1 (v / v), 30 ml). 130 ml of water was added to the obtained elution fraction, acetonitrile was distilled off under reduced pressure, and then freeze-dried to obtain Compound 11 (4.25 g).
- the content of aspartic acid ⁇ -benzyl ester-glycine (4-phenyl-1-butanol) ester bound to compound 11 was calculated from the amount of benzyl alcohol determined in the same manner as in compound 8. As a result, the content of bound aspartic acid ⁇ -benzyl ester-glycine (4-phenyl-1-butanol) ester was 36.3% (w / w), and the ratio of j to the total glutamic acid (i + j + k + m + n) was 95%. .
- An isopropylaminocarbonylisopropylamide group or a hydroxyl group is bonded to the remaining side chain of glutamic acid.
- the content of aspartic acid ⁇ -benzyl ester n-butylamide bound to compound 12 was calculated from the amount of benzyl alcohol obtained by the same procedure as in compound 8. As a result, the content of bound aspartic acid ⁇ -benzyl ester n-butyramide was 28.4% (w / w), and the ratio of j to the total glutamic acid (i + j + k + m + n) was 95%.
- An isopropylaminocarbonylisopropylamide group or a hydroxyl group is bonded to the remaining side chain of glutamic acid.
- the precipitate obtained by the same operation as the compound 8 was dissolved in 50 ml of acetonitrile and 13 ml of water at 5 ° C., and then dissolved in an ion exchange resin (Dow Chemical Dowex 50 (H + ), 10 ml).
- the column was passed through and eluted with acetonitrile / water (5/1 (v / v), 30 ml). 80 ml of water was added to the obtained elution fraction, acetonitrile was distilled off under reduced pressure, and then freeze-dried to obtain Compound 13 (2.94 g).
- the content of aspartic acid ⁇ -benzyl ester-glycine methyl ester bound to compound 13 was calculated from the amount of benzyl alcohol obtained in the same manner as in compound 8. As a result, the content of bound aspartic acid ⁇ -benzyl ester-glycine methyl ester was 26.3% (w / w), and the ratio of j to the total glutamic acid (i + j + k + m + n) was 84%.
- the content of phenylalanine (4-phenyl-1-butanol) ester bound to compound 13 was determined by adding 2N-aqueous sodium hydroxide to compound 13 and stirring at 40 ° C.
- Example 1 Compound 20 (combletastatin A4 was ester-bonded to a block copolymer comprising a methoxypolyethylene glycol moiety having a molecular weight of 12,000 and a polyglutamic acid moiety having a polymerization number of 21 via an amide bond linker of aspartic acid-glycine methyl ester.
- the obtained precipitate was dissolved in 30 ml of acetonitrile and 3 ml of water at 5 ° C., passed through an ion exchange resin (Dow Chemical Dowex 50 (H + ), 3 ml), and acetonitrile / water (10/1 ( v / v), 20 ml). 100 ml of water was added to the obtained elution fraction, acetonitrile was distilled off under reduced pressure, and then freeze-dried to obtain Compound 20 (1.09 g).
- Example 2 Compound 21 (combletastatin A4 was ester-bonded to a block copolymer comprising a methoxypolyethylene glycol moiety having a molecular weight of 12,000 and a polyglutamic acid moiety having a polymerization number of 21 via an amide bond linker of aspartic acid-phenylalanine methyl ester.
- Free combretastatin A4 in compound 21 was not detected, and the amount of unreacted combretastatin A4 in the reaction solution was measured by HPLC. As a result, the content of combretastatin A4 in compound 21 was 11.0% ( w / w), the ratio of i to total glutamic acid (i + j + k + m + n) was 37%.
- Example 3 Compound 22 (combletastatin A4 was ester-bonded to a block copolymer comprising a methoxypolyethylene glycol moiety having a molecular weight of 12,000 and a polyglutamic acid moiety having a polymerization number of 21 via an amide bond linker of aspartic acid-leucine methyl ester.
- Free combretastatin A4 in compound 22 was not detected, and the amount of unreacted combretastatin A4 in the reaction solution was measured by HPLC. As a result, the content of combretastatin A4 in compound 22 was 10.3% ( w / w), the ratio of i to total glutamic acid (i + j + k + m + n) was 32%.
- Example 4 Compound 23 (a block copolymer consisting of a methoxypolyethylene glycol moiety having a molecular weight of 12,000 and a polyglutamic acid moiety having a polymerization number of 21 via an amide bond linker of aspartic acid-glycine (4-phenyl-1-butanol) ester
- Example 5 Compound 24 (combletastatin A4 was ester-bonded to a block copolymer comprising a methoxypolyethylene glycol moiety having a molecular weight of 12,000 and a polyglutamic acid moiety having a polymerization number of 21 via an amide bond linker of aspartic acid n-butylamide.
- Example 6 Compound 25 (a block copolymer comprising a methoxypolyethylene glycol moiety having a molecular weight of 12,000 and a polyglutamic acid moiety having a polymerization number of 21 was added to phenylalanine (4-phenyl-1-butanol) ester and aspartic acid-glycine methyl ester.
- Free combretastatin A4 in compound 25 was not detected, and the amount of unreacted combretastatin A4 in the reaction solution was measured by HPLC. As a result, the content of combretastatin A4 in compound 25 was 9.9% ( w / w), the ratio of i to total glutamic acid (i + j + k + m + n) was 31%.
- Example 7 Compound 26 (Docetaxel is ester-bonded to a block copolymer comprising a methoxypolyethylene glycol moiety having a molecular weight of 12,000 and a polyglutamic acid moiety having a polymerization number of 21 via an amide bond linker of aspartic acid-glycine methyl ester.
- Example 8 Compound 27 (Docetaxel is ester-bonded to a block copolymer comprising a methoxypolyethylene glycol moiety having a molecular weight of 12,000 and a polyglutamic acid moiety having a polymerization number of 21 via an amide bond linker of aspartic acid-phenylalanine methyl ester.
- Example 9 Compound 28 (Docetaxel is ester-bonded to a block copolymer comprising a methoxypolyethylene glycol moiety having a molecular weight of 12,000 and a polyglutamic acid moiety having a polymerization number of 21 via an amide bond linker of aspartic acid-leucine methyl ester.
- Example 10 Compound 29 (a block copolymer consisting of a methoxypolyethylene glycol moiety having a molecular weight of 12,000 and a polyglutamic acid moiety having a polymerization number of 21 via an amide bond linker of aspartic acid-glycine (4-phenyl-1-butanol) ester
- Docetaxel (0.13 g) and compound 17 obtained in Synthesis Example 17 (0.49 g) in 3 ml of DMF Dissolved at 20 ° C., DMAP 0.006 g and DIPC 0.15 m
- Example 13 Compound 32 (a block copolymer consisting of a methoxypolyethylene glycol moiety having a molecular weight of 12000 and a polyglutamic acid moiety having a polymerization number of 21 was passed through an amide bond linker of aspartic acid-glycine (4-phenyl-1-butanol) ester.
- R 1 Me
- R 2 trimethylene group
- R 3 Ac
- R 8 and R 9 hydrogen atom
- R 10 glycine (4 Synthesis of —phenyl-1-butanol) ester residue
- A etoposide residue
- Commercially available etoposide (0.045 g) and compound 17 obtained in Synthesis Example 17 (0.2 g) Is dissolved in 1.3 ml of DMF, and 0.002 g of DMAP and 0.06 ml of DIPC are added at 20 ° C. Stir at 0 ° C. for 20 hours.
- Example 14 Compound 33 (a block copolymer consisting of a methoxypolyethylene glycol moiety having a molecular weight of 12,000 and a polyglutamic acid moiety having a polymerization number of 21 was passed through an amide bond linker of aspartic acid-glycine (4-phenyl-1-butanol) ester.
- R 1 Me
- R 2 trimethylene group
- R 3 Ac
- R 8 and R 9 hydrogen atom
- R 10 glycine (4 -Phenyl-1-butanol) ester residue
- A prednisolone residue
- Commercial prednisolone (0.048 g) and compound 17 obtained in Synthesis Example 17 (0.2 g) Is dissolved in 1.3 ml of DMF, and at 20 ° C., DMAP 0.002 g, DIPC 0.06 m was added and stirred at 20 ° C. for 20 hours.
- paclitaxel in compound 34 was not detected, and the amount of unreacted paclitaxel in the reaction solution was measured by HPLC. As a result, the paclitaxel content in compound 34 was 22.0% (w / w), and total glutamic acid (i + j + k + m + n ) was 34%.
- Commercially available adenosine (0.0123 g) and compound 15 (0.119 g) obtained in Synthesis Example 15 were dissolved in 0.8 ml DMF, and 0.0014 g DMAP, DIPC0 at 20 ° C.
- Example 17 Compound 36 (capecitabine bound to a block copolymer comprising a methoxypolyethylene glycol moiety having a molecular weight of 12,000 and a polyglutamic acid moiety having a polymerization number of 21 via an amide bond linker of aspartic acid-phenylalanine methyl ester
- R 1 Me of general formula (III)
- R 2 trimethylene group
- R 3 Ac
- R 8 and R 9 hydrogen atom
- R 10 phenylalanine methyl ester residue
- A capecitabine residue
- Commercial capecitabine (0.0138 g) and compound 15 (0.099 g) obtained in Synthesis Example 15 were dissolved in 0.6 ml of DMF, and at 20 ° C., DMAP 0.0017 g, DIPC0 0.03 ml was added and stirred at 20 ° C.
- Example 18 Compound 37 (a block copolymer comprising a methoxypolyethylene glycol moiety having a molecular weight of 12,000 and a polyglutamic acid moiety having a polymerization number of 21 via an amide bond linker of aspartic acid-glycine (4-phenyl-1-butanol) ester
- R 1 Me
- R 2 trimethylene group
- R 3 Ac
- R 8 and R 9 hydrogen atom in the general formula (III)
- R 10 glycine (4 -Phenyl-1-butanol) ester residue
- Example 17 (0.1 g) Is dissolved in 0.6 ml of DMF, and 0.001 g of DMAP and 0.03 ml of DIPC are added at 20 ° C
- Test Example 1 Drug Release in the Absence of Enzyme of Combretastatin A4 Conjugate Compound 20 to Compound 25, Polyethylene Glycol-Polyglutamate Block Copolymer Prepared as a Comparative Compound by the Method described in International Publication No. 2008/10463 Pamphlet
- the combretastatin conjugate (PEG-Glu-CA4) and polyethylene glycol-polyaspartic acid block copolymer combretastatin conjugate (PEG-Asp-CA4) in PBS (phosphate buffered saline; pH 7. 1) was dissolved at a concentration of 1 mg / ml and incubated at 37 ° C.
- Combretastatin A4 released from the polymer conjugate was analyzed by HPLC and quantified using a standard curve. The ratio between the quantitative value and the total drug amount determined from the drug content of the polymer conjugate is shown in FIG.
- the polymer conjugates of the present invention (compounds 20 to 25) release combretastatin A4 even in the absence of hydrolase, and the release rates are all PEG-Glu-CA4. It was faster. Moreover, the release rate could be greatly changed by the difference in the R 10 substituent bonded to aspartic acid. These results indicate that the polymer conjugate of the present invention is excellent in the ability to adjust the drug release rate.
- Test Example 2 Drug Release in the absence of Enzyme of Docetaxel Conjugate Compound 26 to Compound 30, and Docetaxel of Polyethylene Glycol-Polyaspartic Acid Block Copolymer Prepared as a Comparative Compound by the Method described in International Publication No. 2007/11121 Pamphlet
- the conjugate (PEG-Asp-DTX) was dissolved in PBS (phosphate buffered saline; pH 7.1) at a concentration of 1 mg / ml and incubated at 37 ° C.
- Docetaxel released from the polymer conjugate was analyzed by HPLC and quantified using a standard curve. The ratio between the quantitative value and the total drug amount determined from the drug content of the polymer conjugate is shown in FIG.
- the release rate of the polymer conjugate of the present invention can be greatly changed by the R 10 substituent bonded to aspartic acid.
- Compound 26 and Compound 30 have PEG-Asp- It was possible to release docetaxel faster than DTX. These results indicate that the polymer conjugate of the present invention is excellent in the ability to adjust the drug release rate.
- Test Example 3 Gemcitabine, Etoposide, Prednisolone, Paclitaxel, Drug Release in the Absence of Enzyme-Linked Polymer Conjugate
- Compound 31 (Gemcitabine Conjugate), Compound 32 (Etoposide Conjugate), Compound 33 (Prednisolone Conjugate) ), Compound 34 (paclitaxel conjugate) and Compound 35 (adenosine conjugate) were dissolved in PBS (phosphate buffered saline; pH 7.1) at a concentration of 1 mg / ml and incubated at 37 ° C.
- PBS phosphate buffered saline; pH 7.1
- Each drug released from the polymer conjugate was analyzed by HPLC and quantified using a standard curve. The ratio between the quantitative value and the total drug amount determined from the drug content of the polymer conjugate is shown in FIG.
- the polymer conjugate of the physiologically active compound of the present invention shows that the physiologically active substance can be released without hydrolase.
- Test Example 4 Release of Drug in the Absence of Enzyme of Polymer Conjugate Bound with Capecitabine Compound 36 and Compound 37 were each dissolved in PBS (phosphate buffered saline; pH 7.1) at a concentration of 1 mg / ml, Incubated at 37 ° C. Each drug released from the polymer conjugate was analyzed by HPLC and quantified using a standard curve. The ratio between the quantitative value and the total drug amount determined from the drug content of the polymer conjugate is shown in FIG.
- PBS phosphate buffered saline
- the polymer conjugate of the physiologically active compound of the present invention shows that the physiologically active substance can be released without a hydrolase. Furthermore, by varying the R 10, it shows that it is possible to adjust the release rate.
- Test Example 5 Antitumor Activity Test of Combretastatin A4 Conjugate Mouse colon cancer Colon 26 subcultured subcutaneously in mice was made into a block of about 2 mm square and transplanted subcutaneously on the dorsal side of female CDF1 mice using a trocar. did. From the 8th day after tumor transplantation, the polymer conjugate of the present invention (Compound 22) or the control drug (combretastatin A4 phosphate ester; CA4P, PEG-Glu-CA4 or PEG-Asp-CA4), respectively, combretastatin The same amount per body weight in terms of A4 was administered once into the mouse tail vein. Each compound was used after being dissolved in a 5% glucose solution.
- the major axis (Lmm) and minor axis (Wmm) of the tumor were measured with calipers, and the tumor volume was calculated by (LxW 2 ) / 2 and expressed as a relative tumor volume ratio to the tumor volume of the untreated group (control). It was shown in 1.
- Test Example 6 Effect of Combretastatin A4 Conjugate on Myocardium As a side effect of combretastatins, myocardial damage is known, and it is released into the blood when damaged by enzymes contained in large amounts in the myocardium and nerves. The change in the titer of creatinine phosphokinase (CPK) was observed, and the degree of side effects of the compound of the present invention was compared with known compounds.
- CPK creatinine phosphokinase
- Compound 22 as a compound of the present invention and CA4P, PEG-Glu-CA4, and PEG-Asp-CA4 as a comparative compound were administered by a single tail vein.
- Blood was collected from the abdominal aorta under ether anesthesia, and creatinine phosphokinase (CPK) in plasma was measured.
- CPK creatinine phosphokinase
- the transition of average titer (IU / L) is shown in Table 2.
- the polymer conjugate of the present invention (Compound 22) exhibited an antitumor effect without increasing CPK at a dose of 25 mg / kg.
- the dose of 50 mg / kg showed a stronger antitumor effect than that of 25 mg / kg, and CPK was transient but recovered at 24 hours although it increased at 6 hours.
- combretastatin A4 phosphate which is a control drug, showed only a weak anti-tumor effect at a dose of 200 mg / kg despite a marked increase in CPK.
- PEG-Glu-CA4 showed a strong antitumor effect at a dose of 50 mg / kg, but CPK did not recover even after 24 hours, and did not show an antitumor effect at a dose of 25 mg / kg. .
- PEG-Asp-CA4 showed an anti-tumor effect close to the dose of 25 mg / kg of Compound 22 at a dose of 12.5 mg / kg, but CPK also increased at this dose, and CPK increased and anti-tumor effect could not deviate.
- Test Example 7 Antitumor Activity Test of Docetaxel Conjugate Mouse colon cancer Colon26 subcultured subcutaneously in mice was made into a block of about 2 mm square and transplanted subcutaneously on the dorsal side of female CDF1 mice using a trocar. From the 8th day after tumor transplantation, the polymer conjugate of the present invention (compound 30) or the control drug (docetaxel; DTX or PEG-Asp-DTX) was administered once in the tail vein of the mouse in the same amount per docetaxel. Administered. Docetaxel was dissolved in absolute ethanol and Cremophor (manufactured by Sigma) and diluted with physiological saline at the time of use.
- the polymer conjugate of the present invention exhibits a stronger antitumor effect than docetaxel even at half the dose of docetaxel (50 mg / kg), and is stronger at 100 mg / kg. It showed antitumor effect.
- PEG-Asp-DTX which is a control drug, showed a strong antitumor effect at a dose of 100 mg / kg, but showed an effect equal to or lower than that of DTX at a dose of 50 mg / kg.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Polymers & Plastics (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Polyamides (AREA)
- Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
Abstract
Description
R6は一般式(VI)
R7は(C1~C30)アルコキシ基、(C1~C30)アラルキルオキシ基、(C1~C30)アルキルアミノ基、ジ(C1~C30)アルキルアミノ基、カルボキシ基が保護されたアミノ酸及びNR12CONHR13からなる群から選ばれる置換基を示し、R12、R13は同一でも異なっていてもよく(C3~C6)環状アルキル基若しくは三級アミノ基で置換されていてもよい(C1~C5)アルキル基を示し、bは5~11500の整数を示し、iは1~200の整数を示し、j、k、m、nは各々0~200の整数を示し、且つi+j+k+m+nは2~200の整数を示す]
で表される化合物である前記(1)~(3)のいずれか一項に記載の生理活性物質の高分子結合体。
R4は前記一般式(I)あるいは一般式(II)[式中、R8、R9、R10、CX-CY、Aは前記と同じ意味を示す]で表わされる置換基を示し、
R5は前記一般式(IV)あるいは一般式(V)[式中、R8、R9、R10、CX-CYは前記と同じ意味を示し、R11は水酸基、置換基を有していてもよい芳香族アミノ基、置換基を有していてもよい(C1~C30)アルコキシ基、置換基を有していてもよい(C1~C30)アラルキルオキシ基、置換基を有していてもよい(C1~C30)アルキルアミノ基、置換基を有していてもよいジ(C1~C30)アルキルアミノ基、カルボキシ基が保護されたアミノ酸及びNR12CONHR13からなる群から選ばれるひとつ以上の置換基を示し、R12、R13は同一でも異なっていてもよく(C3~C6)環状アルキル基若しくは三級アミノ基で置換されていてもよい(C1~C5)アルキル基を示す]で表わされる置換基を示し、
R6は前記一般式(VI)[式中、式中、R8、R9、R10、CX-CYは前記と同じ意味を示す]で表わされる置換基を示し、
R7は(C1~C30)アルコキシ基、(C1~C30)アラルキルオキシ基、(C1~C30)アルキルアミノ基、ジ(C1~C30)アルキルアミノ基、カルボキシ基が保護されたアミノ酸及びNR12CONHR13からなる群から選ばれる置換基を示し、R12、R13は同一でも異なっていてもよく(C3~C6)環状アルキル基若しくは三級アミノ基で置換されていてもよい(C1~C5)アルキル基を示し、bは5~11500の整数を示し、iは1~200の整数を示し、j、k、m、nは各々0~200の整数を示し、且つi+j+k+m+nは2~200の整数を示す]で表される化合物が好ましい。
なお、本発明における分子量とはGPC法で測定した重量平均分子量である。
グリシン塩酸塩(和光純薬製)1.0gと、4-フェニル-1-ブタノール(東京化成製)6.7gをジオキサン5mlに懸濁後、4N-塩酸/ジオキサン5mlを加え、室温にて3日間攪拌した。不溶物を濾別しジオキサン5mlで洗浄した。濾液と洗液を合わせた溶液にジエチルエーテル100mlを加え、室温にて1時間攪拌した。析出した沈殿を濾取して減圧下乾燥し化合物1の塩酸塩1.7gを得た。
1H-NMR(400MHz,DMSO-d6,ppm):1.63(m,4H)、2.61(m,2H)、3.80(s,2H)、4.18(m,2H)、7.1-7.3(m,5H)、8.0-8.6(br,2H)
フェニルアラニン塩酸塩(国産化学製)1.5gと、4-フェニル-1-ブタノール(東京化成製)6.7gをジオキサン5mlに懸濁後、4N-塩酸/ジオキサン5mlを加え、室温にて3日間攪拌した。次いで、実施例1と同様な操作で化合物2の塩酸塩1.6gを得た。
1H-NMR(400MHz,DMSO-d6,ppm):1.46(m,4H)、2.53(m,2H)、2.97-3.18(m,2H)、4.06(m,2H)、4.27(dd,1H)、7.2-7.4(m,10H)、8.0-8.8(br,2H)
N-(tert-ブトキシカルボニル)アスパラギン酸β-ベンジルエステル(国産化学製)0.97gと、グリシンメチルエステル塩酸塩(国産化学製)0.38gをDMF19mlに溶解後、トリエチルアミン0.42ml、HOBt0.51g、WSC塩酸塩0.63gを加え、室温にて一夜攪拌した。反応液を酢酸エチルにて抽出し、冷水、希塩酸、飽和炭酸水素ナトリウム水溶液、飽和食塩水の順で洗浄した。減圧下、酢酸エチルを留去し真空乾燥して固形物1.2gを得た。得られた固形物を酢酸エチル15mlに溶解後、4N-HCl/酢酸エチル15mlを加え、室温にて1時間攪拌した。反応液にジエチルエーテル120mlを加え、室温にて2時間攪拌後、傾斜法にて溶媒を除去し、続いてジエチルエーテルで固形物を洗浄した。オイル状の固形物を減圧下乾燥し化合物3の塩酸塩0.86gを得た。
1H-NMR(400MHz,DMSO-d6,ppm):2.94(m,4H)、3.63(s,3H)、3.92(ddd,2H)、4.18(dd,1H)、5.15(m,2H)、7.3-7.4(m,5H)、8.3(br,2H)、8.93(t,1H)
N-(tert-ブトキシカルボニル)アスパラギン酸β-ベンジルエステル(国産化学製)1.3gと、フェニルアラニンメチルエステル塩酸塩(国産化学製)0.86gをDMF23mlに溶解後、トリエチルアミン0.56ml、HOBt0.73g、WSC塩酸塩0.84gを加え、室温にて一夜攪拌した。次いで、実施例3と同様な操作にて固形物2.0gを得た。得られた固形物を酢酸エチル20mlに溶解後、4N-塩酸/酢酸エチル20mlを加え、室温にて1時間攪拌し、次いで、実施例3と同様な操作にて得られた固形物を減圧下乾燥し化合物4の塩酸塩1.65gを得た。
1H-NMR(400MHz,DMSO-d6,ppm):2.64(m,2H)、2.98(dd,2H)、3.09(dd,2H)、3.64(s,3H)、4.07(dd,1H)、4.60(m,1H)、5.12(m,2H)、7.1-7.3(m,10H)、8.0(br,2H)、8.96(d,1H)
N-(tert-ブトキシカルボニル)アスパラギン酸β-ベンジルエステル(国産化学製)1.3gと、ロイシンメチルエステル塩酸塩(国産化学製)0.73gをDMF23mlに溶解後、トリエチルアミン0.56ml、HOBt0.73g、WSC塩酸塩0.84gを加え、室温にて一夜攪拌した。次いで、実施例3と同様な操作にて固形物1.9gを得た。得られた固形物を酢酸エチル20mlに溶解後、4N-塩酸/酢酸エチル20mlを加え、室温にて1時間攪拌し、次いで、実施例3と同様な操作にて得られた固形物を減圧下乾燥し化合物5の塩酸塩1.51gを得た。
1H-NMR(400MHz,DMSO-d6,ppm):0.88(dd,6H)、1.5-1.8(m,3H)、2.84(dd,2H)、2.95(dd,2H)、3.62(s,3H)、4.15(dd,1H)、4.32(m,1H)、5.17(m,2H)、7.3-7.4(m,5H)、8.0(br,2H)、8.79(d,1H)
N-(tert-ブトキシカルボニル)アスパラギン酸β-ベンジルエステル(国産化学製)1.3gと、合成例1で得られた化合物1の塩酸塩0.97gをDMF23mlに溶解後、トリエチルアミン0.56ml、HOBt0.73g、WSC塩酸塩0.84gを加え、室温にて一夜攪拌した。次いで、実施例3と同様な操作にて固形物2.0gを得た。得られた固形物を酢酸エチル20mlに溶解後、4N-塩酸/酢酸エチル20mlを加え、室温にて1時間攪拌し、次いで、実施例3と同様な操作にて得られた固形物を減圧下乾燥し化合物6の塩酸塩1.72gを得た。
1H-NMR(400MHz,DMSO-d6,ppm):1.59(m,4H)、2.59(m,2H)、2.80(dd,2H)、2.93(dd,2H)、3.91(ddd,2H)、4.07(m,3H)、5.15(m,2H)、7.2-7.4(m,10H)、8.8(br,1H)
N-(tert-ブトキシカルボニル)アスパラギン酸β-ベンジルエステル(国産化学製)1.3gと、n-ブチルアミン0.40gをDMF23mlに溶解後、HOBt0.73g、WSC塩酸塩0.84gを加え、室温にて一夜攪拌した。次いで、実施例3と同様な操作にて固形物1.54gを得た。得られた固形物を酢酸エチル20mlに溶解後、4N-塩酸/酢酸エチル20mlを加え、室温にて1時間攪拌し、次いで、実施例3と同様な操作にて得られた固形物を減圧下乾燥し化合物7の塩酸塩1.24gを得た。
1H-NMR(400MHz,DMSO-d6,ppm):0.85(t,3H)、1.27(m,2H)、1.37(m,2H)、2.91(ddd,2H)、3.09(m,2H)、4.02(dd,2H)、5.14(m,2H)、7.39(m,5H)、8.15(br,2H)、8.43(t,1H)
国際公開2006/120914号パンフレットに記載された方法によって調製したメトキシポリエチレングリコール-ポリグルタミン酸ブロック共重合体2.0gと、合成例3で得られた化合物3(0.86g)をDMF40mlに溶解し、25℃にてトリエチルアミン0.36ml、DMAP0.04g、DIPC0.90mlを加えて、25℃にて20時間撹拌した。反応液にエタノール80ml及びジイソプロピルエーテル320mlを加えて室温にて2時間攪拌し、沈析物を濾取してエタノール/ジイソプロピルエーテル(1/4(v/v)、40ml)で洗浄した。得られた沈析物をアセトニトリル44ml及び水11mlに5℃にて溶解後、イオン交換樹脂(ダウケミカル製ダウエックス50(H+)、5ml)に通塔し、アセトニトリル/水(5/1(v/v)、15ml)にて溶出した。得られた溶出画分に75mlの水を加え、アセトニトリルを減圧下留去し、次いで、凍結乾燥することにより化合物8(2.71g)を得た。
国際公開2006/120914号パンフレットに記載された方法によって調製したメトキシポリエチレングリコール-ポリグルタミン酸ブロック共重合体3.09gと、合成例4で得られた化合物4(1.65g)をDMF55mlに溶解し、25℃にてトリエチルアミン0.55ml、DMAP0.05g、DIPC1.37mlを加えて、25℃にて20時間撹拌した。次いで、化合物8と同様な操作にて得られた沈析物を、アセトニトリル70ml及び水20mlに5℃にて溶解後、イオン交換樹脂(ダウケミカル製ダウエックス50(H+)、10ml)に通塔し、アセトニトリル/水(5/1(v/v)、30ml)にて溶出した。得られた溶出画分に130mlの水を加え、アセトニトリルを減圧下留去し、次いで、凍結乾燥することにより化合物9(4.52g)を得た。
国際公開2006/120914号パンフレットに記載された方法によって調製したメトキシポリエチレングリコール-ポリグルタミン酸ブロック共重合体3.08gと、合成例5で得られた化合物5(1.51g)をDMF54mlに溶解し、25℃にてトリエチルアミン0.54ml、DMAP0.05g、DIPC1.36mlを加えて、25℃にて20時間撹拌した。次いで、前記化合物8と同様な操作にて得られた沈析物を、アセトニトリル70ml及び水20mlに5℃にて溶解後、イオン交換樹脂(ダウケミカル製ダウエックス50(H+)、10ml)に通塔し、アセトニトリル/水(5/1(v/v)、30ml)にて溶出した。得られた溶出画分に130mlの水を加え、アセトニトリルを減圧下留去し、次いで、凍結乾燥することにより化合物10(4.26g)を得た。
国際公開2006/120914号パンフレットに記載された方法によって調製したメトキシポリエチレングリコール-ポリグルタミン酸ブロック共重合体2.84gと、合成例6で得られた化合物6(1.72g)をDMF50mlに溶解し、25℃にてトリエチルアミン0.54ml、DMAP0.05g、DIPC1.26mlを加えて、25℃にて20時間撹拌した。次いで、前記化合物8と同様な操作にて得られた沈析物を、アセトニトリル70ml及び水20mlに5℃にて溶解後、イオン交換樹脂(ダウケミカル製ダウエックス50(H+)、10ml)に通塔し、アセトニトリル/水(5/1(v/v)、30ml)にて溶出した。得られた溶出画分に130mlの水を加え、アセトニトリルを減圧下留去し、次いで、凍結乾燥することにより化合物11(4.25g)を得た。
国際公開2006/120914号パンフレットに記載された方法によって調製したメトキシポリエチレングリコール-ポリグルタミン酸ブロック共重合体2.92gと、合成例7で得られた化合物7(1.24g)をDMF52mlに溶解し、25℃にてトリエチルアミン0.55ml、DMAP0.05g、DIPC1.30mlを加えて、25℃にて20時間撹拌した。次いで、前記化合物8と同様な操作にて得られた沈析物を、アセトニトリル60ml及び水15mlに5℃にて溶解後、イオン交換樹脂(ダウケミカル製ダウエックス50(H+)、10ml)に通塔し、アセトニトリル/水(5/1(v/v)、30ml)にて溶出した。得られた溶出画分に100mlの水を加え、アセトニトリルを減圧下留去し、次いで、凍結乾燥することにより化合物12(3.89g)を得た。
国際公開2006/120914号パンフレットに記載された方法によって調製したメトキシポリエチレングリコール-ポリグルタミン酸ブロック共重合体2.17gと、合成例2で得られた化合物2(0.1g)及び合成例3で得られた化合物3(0.87g)をDMF38mlに溶解し、25℃にてトリエチルアミン0.41ml、DMAP0.04g、DIPC0.97mlを加えて、25℃にて20時間撹拌した。次いで、前記化合物8と同様な操作にて得られた沈析物を、アセトニトリル50ml及び水13mlに5℃にて溶解後、イオン交換樹脂(ダウケミカル製ダウエックス50(H+)、10ml)に通塔し、アセトニトリル/水(5/1(v/v)、30ml)にて溶出した。得られた溶出画分に80mlの水を加え、アセトニトリルを減圧下留去し、次いで、凍結乾燥することにより化合物13(2.94g)を得た。
合成例8で得られた化合物8(2.73g)をDMF68mlに溶解し、5%パラジウム炭素(水分含量50%)0.27gを加え、25℃で一夜加水素分解反応に供した。5%パラジウム炭素を濾過し酢酸エチル80mlで洗浄後、濾液にヘプタン400ml及び酢酸エチル120mlを加えて室温にて2時間攪拌した。沈析物を濾取し真空乾燥して化合物14(2.31g)を得た。
合成例9で得られた化合物9(4.51g)をDMF113mlに溶解し、5%パラジウム炭素(水分含量50%)0.45gを加え、25℃で一夜加水素分解反応に供した。次いで、化合物14と同様な操作にて化合物15(3.81g)を得た。
合成例10で得られた化合物10(4.21g)をDMF105mlに溶解し、5%パラジウム炭素(水分含量50%)0.42gを加え、25℃で一夜加水素分解反応に供した。次いで、化合物14と同様な操作にて化合物16(3.61g)を得た。
合成例11で得られた化合物11(4.20g)をDMF105mlに溶解し、5%パラジウム炭素(水分含量50%)0.42gを加え、25℃で一夜加水素分解反応に供した。次いで、化合物14と同様な操作にて化合物17(3.58g)を得た。
合成例12で得られた化合物12(3.84g)をDMF96mlに溶解し、5%パラジウム炭素(水分含量50%)0.38gを加え、25℃で一夜加水素分解反応に供した。次いで、化合物14と同様な操作にて化合物18(3.29g)を得た。
合成例13で得られた化合物13(2.89g)をDMF72mlに溶解し、5%パラジウム炭素(水分含量50%)0.29gを加え、25℃で一夜加水素分解反応に供した。次いで、化合物14と同様な操作にて化合物19(2.48g)を得た。
J.Med.Chem.,38,1666-1672(1995)記載の方法で作成したコンブレタスタチンA4(0.13g)及び合成例14で得られた化合物14(0.97g)をDMF7mlに溶解し、20℃にてDMAP0.013g、DIPC0.32mlを加え、20℃で20時間撹拌した。反応液に酢酸エチル20ml及びジイソプロピルエーテル80mlを加え、室温にて2時間攪拌後、沈析物を濾取して酢酸エチル/ジイソプロピルエーテル(1/4(v/v)、20ml)で洗浄した。得られた沈析物をアセトニトリル30ml及び水3mlに5℃にて溶解後、イオン交換樹脂(ダウケミカル製ダウエックス50(H+)、3ml)に通塔し、アセトニトリル/水(10/1(v/v)、20ml)にて溶出した。得られた溶出画分に100mlの水を加え、アセトニトリルを減圧下留去し、次いで、凍結乾燥することにより化合物20(1.09g)を得た。
化合物20の水溶液(1mg/ml)を用いてガウス分布分析を行ったところ、18nm(volume weighting)だった。よって、化合物20は水中でミセルを形成しているものと考えられた。
コンブレタスタチンA4(0.13g)及び合成例15で得られた化合物15(1.06g)をDMF7mlに溶解し、20℃にてDMAP0.013g、DIPC0.32mlを加え、20℃で20時間撹拌した。次いで、前記化合物20と同様の操作にて化合物21(1.17g)を得た。
コンブレタスタチンA4(0.13g)及び合成例16で得られた化合物16(1.15g)をDMF7mlに溶解し、20℃にてDMAP0.013g、DIPC0.32mlを加え、20℃で20時間撹拌した。次いで、前記化合物20と同様の操作にて化合物22(1.26g)を得た。
コンブレタスタチンA4(0.13g)及び合成例17で得られた化合物17(1.07g)をDMF7mlに溶解し、20℃にてDMAP0.013g、DIPC0.32mlを加え、20℃で20時間撹拌した。次いで、前記化合物20と同様の操作にて化合物23(1.17g)を得た。
化合物23の水溶液(1mg/ml)を用いてガウス分布分析を行ったところ、39nm(volume weighting)だった。よって、化合物23は水中でミセルを形成しているものと考えられた。
コンブレタスタチンA4(0.13g)及び合成例18で得られた化合物18(0.91g)をDMF7mlに溶解し、20℃にてDMAP0.013g、DIPC0.32mlを加え、20℃で20時間撹拌した。次いで、前記化合物20と同様の操作にて化合物24(0.93g)を得た。
化合物24の水溶液(1mg/ml)を用いてガウス分布分析を行ったところ、16nm(volume weighting)だった。よって、化合物24は水中でミセルを形成しているものと考えられた。
コンブレタスタチンA4(0.13g)及び合成例19で得られた化合物19(1.05g)をDMF7mlに溶解し、20℃にてDMAP0.013g、DIPC0.32mlを加え、20℃で20時間撹拌した。次いで、前記化合物20と同様の操作にて化合物25(1.14g)を得た。
市販のドセタキセル(0.13g)及び合成例14で得られた化合物14(0.45g)をDMF3mlに溶解し、20℃にてDMAP0.006g、DIPC0.15mlを加え、20℃で20時間撹拌した。反応液にエタノール4.5ml、酢酸エチル4.5ml及びジイソプロピルエーテル36mlを加え、室温にて2時間攪拌後、沈析物を濾取してエタノール/ジイソプロピルエーテル(1/4(v/v)、10ml)で洗浄した。得られた沈析物をアセトニトリル20ml及び水2mlに5℃にて溶解後、イオン交換樹脂(ダウケミカル製ダウエックス50(H+)、2ml)に通塔し、アセトニトリル/水(10/1(v/v)、10ml)にて溶出した。得られた溶出画分に50mlの水を加え、アセトニトリルを減圧下留去し、次いで、凍結乾燥することにより化合物26(0.54g)を得た。
ドセタキセル(0.13g)及び合成例15で得られた化合物15(0.48g)をDMF3mlに溶解し、20℃にてDMAP0.006g、DIPC0.15mlを加え、20℃で20時間撹拌した。次いで、前記化合物26と同様の操作にて化合物27(0.58g)を得た。
市販のドセタキセル(0.13g)及び合成例16で得られた化合物16(0.52g)をDMF3mlに溶解し、20℃にてDMAP0.006g、DIPC0.15mlを加え、20℃で20時間撹拌した。次いで、化合物26と同様の操作にて化合物28(0.64g)を得た。
ドセタキセル(0.13g)及び合成例17で得られた化合物17(0.49g)をDMF3mlに溶解し、20℃にてDMAP0.006g、DIPC0.15mlを加え、20℃で20時間撹拌した。次いで、化合物26と同様の操作にて化合物29(0.58g)を得た。
ドセタキセル(0.13g)及び合成例19で得られた化合物19(0.48g)をDMF3mlに溶解し、20℃にてDMAP0.006g、DIPC0.15mlを加え、20℃で20時間撹拌した。次いで、化合物26と同様の操作にて化合物30(0.58g)を得た。
市販のゲムシタビン(0.13g)及び合成例15で得られた化合物15(1.02g)をDMF7mlに溶解し、20℃にてDMAP0.012g、DIPC0.31mlを加え、20℃で20時間撹拌した。反応液にエタノール20ml及びジイソプロピルエーテル80mlを加え、室温にて2時間攪拌後、沈析物を濾取しエタノール/ジイソプロピルエーテル(1/4(v/v)、30ml)で洗浄した。得られた沈析物をアセトニトリル30ml及び水6mlに5℃にて溶解後、イオン交換樹脂(ダウケミカル製ダウエックス50(H+)、3ml)に通塔し、アセトニトリル/水(10/1(v/v)、30ml)にて溶出した。得られた溶出画分に110mlの水を加えた後、アセトニトリルを減圧下留去し、次いで、凍結乾燥することにより化合物31(1.13g)を得た。
市販のエトポシド(0.045g)及び合成例17で得られた化合物17(0.2g)をDMF1.3mlに溶解し、20℃にてDMAP0.002g、DIPC0.06mlを加え、20℃で20時間撹拌した。反応液に酢酸エチル4ml及びジイソプロピルエーテル16mlを加え、室温にて2時間攪拌後、沈析物を濾取し、酢酸エチル/ジイソプロピルエーテル(1/4(v/v)、5ml)で洗浄した。得られた沈析物をアセトニトリル12ml及び水2mlに5℃にて溶解後、イオン交換樹脂(ダウケミカル製ダウエックス50(H+)、0.5ml)に通塔し、アセトニトリル/水(10/1(v/v)、2ml)にて溶出した。得られた溶出画分に12mlの水を加え、アセトニトリルを減圧下留去し、次いで、凍結乾燥することによって化合物32(0.233g)を得た。
市販のプレドニゾロン(0.048g)及び合成例17で得られた化合物17(0.2g)をDMF1.3mlに溶解し、20℃にてDMAP0.002g、DIPC0.06mlを加え、20℃で20時間撹拌した。反応液にエタノール4ml及びジイソプロピルエーテル16mlを加え、室温にて2時間攪拌後、沈析物を濾取し、エタノール/ジイソプロピルエーテル(1/4(v/v)、5ml)で洗浄した。得られた沈析物をアセトニトリル12ml及び水2mlに5℃にて溶解後、イオン交換樹脂(ダウケミカル製ダウエックス50(H+)、0.5ml)に通塔し、アセトニトリル/水(10/1(v/v)、2ml)にて溶出した。得られた溶出画分に12mlの水を加え、アセトニトリルを減圧下留去し、次いで、凍結乾燥することによって化合物33(0.239g)を得た。
化合物33の水溶液(1mg/ml)を用いてガウス分布分析を行ったところ、50nm(volume weighting)だった。よって、化合物33は水中でミセルを形成しているものと考えられた。
市販のパクリタキセル(0.029g)及び合成例19で得られた化合物19(0.10g)をDMF0.7mlに溶解し、20℃にてDMAP0.0012g、DIPC0.031mlを加え、20℃で20時間撹拌した。反応液にエタノール2ml及びジイソプロピルエーテル8mlを加え、室温にて2時間攪拌後、沈析物を濾取しエタノール/ジイソプロピルエーテル(1/4(v/v)、3ml)で洗浄した。得られた沈析物をアセトニトリル6ml及び水1.5mlに5℃にて溶解後、イオン交換樹脂(ダウケミカル製ダウエックス50(H+)、0.5ml)に通塔し、アセトニトリル/水(10/1(v/v)、6ml)にて溶出した。得られた溶出画分に12mlの水を加えた後、アセトニトリルを減圧下留去し、次いで、凍結乾燥することにより化合物34(0.121g)を得た。
市販のアデノシン(0.0123g)及び合成例15で得られた化合物15(0.119g)をDMF0.8mlに溶解し、20℃にてDMAP0.0014g、DIPC0.036mlを加え、20℃で20時間撹拌した。反応液にエタノール2.3ml及びジイソプロピルエーテル9.2mlを加え、室温にて2時間攪拌後、沈析物を濾取しエタノール/ジイソプロピルエーテル(1/4(v/v)、3ml)で洗浄した。得られた沈析物をアセトニトリル6ml及び水1.5mlに5℃にて溶解後、イオン交換樹脂(ダウケミカル製ダウエックス50(H+)、0.5ml)に通塔し、アセトニトリル/水(10/1(v/v)、6ml)にて溶出した。得られた溶出画分に12mlの水を加えた後、アセトニトリルを減圧下留去し、次いで、凍結乾燥することにより化合物35(0.127g)を得た。
市販のカペシタビン(0.0138g)及び合成例15で得られた化合物15(0.099g)をDMF0.6mlに溶解し、20℃にてDMAP0.0017g、DIPC0.03mlを加え、20℃で20時間撹拌した。反応液にエタノール2ml及びジイソプロピルエーテル8mlを加え、室温にて2時間攪拌後、沈析物を濾取しエタノール/ジイソプロピルエーテル(1/4(v/v)、3ml)で洗浄した。得られた沈析物をアセトニトリル4ml及び水1mlに5℃にて溶解後、イオン交換樹脂(ダウケミカル製ダウエックス50(H+)、0.2ml)に通塔し、アセトニトリル/水(10/1(v/v)、6ml)にて溶出した。得られた溶出画分に11mlの水を加えた後、アセトニトリルを減圧下留去し、次いで、凍結乾燥することにより化合物36(0.112g)を得た。
市販のカペシタビン(0.014g)及び合成例17で得られた化合物17(0.1g)をDMF0.6mlに溶解し、20℃にてDMAP0.001g、DIPC0.03mlを加え、20℃で20時間撹拌した。反応液にエタノール2ml及びジイソプロピルエーテル8mlを加え、室温にて2時間攪拌後、沈析物を濾取し、エタノール/ジイソプロピルエーテル(1/4(v/v)、3ml)で洗浄した。得られた沈析物をアセトニトリル4ml及び水1mlに5℃にて溶解後、イオン交換樹脂(ダウケミカル製ダウエックス50(H+)、0.2ml)に通塔し、アセトニトリル/水(10/1(v/v)、6ml)にて溶出した。得られた溶出画分に11mlの水を加え、アセトニトリルを減圧下留去し、次いで、凍結乾燥することによって化合物37(0.111g)を得た。
化合物20~化合物25、比較化合物として国際公開第2008/10463号パンフレット記載の方法で作成したポリエチレングリコール-ポリグルタミン酸ブロック共重合体のコンブレタスタチン結合体(PEG-Glu-CA4)及びポリエチレングリコール-ポリアスパラギン酸ブロック共重合体のコンブレタスタチン結合体(PEG-Asp-CA4)をそれぞれPBS(リン酸緩衝生理食塩水;pH7.1)に1mg/mlの濃度で溶解し、37℃にてインキュベートした。該高分子結合体より放出されたコンブレタスタチンA4を、HPLCにて分析し標準曲線を用いて定量した。定量値と高分子結合体の薬剤含有量から求めた全薬剤量との比を図1に示した。
化合物26~化合物30、比較化合物として国際公開第2007/111211号パンフレット記載の方法で作成したポリエチレングリコール-ポリアスパラギン酸ブロック共重合体のドセタキセル結合体(PEG-Asp-DTX)をそれぞれPBS(リン酸緩衝生理食塩水;pH7.1)に1mg/mlの濃度で溶解し、37℃にてインキュベートした。該高分子結合体より放出されたドセタキセルを、HPLCにて分析し標準曲線を用いて定量した。定量値と高分子結合体の薬剤含有量から求めた全薬剤量との比を図2に示した。
化合物31(ゲムシタビン結合体)、化合物32(エトポシド結合体)、化合物33(プレドニゾロン結合体)、化合物34(パクリタキセル結合体)、化合物35(アデノシン結合体)をそれぞれPBS(リン酸緩衝生理食塩水;pH7.1)に1mg/mlの濃度で溶解し、37℃にてインキュベートした。該高分子結合体より放出された各薬剤を、HPLCにて分析し標準曲線を用いて定量した。定量値と高分子結合体の薬剤含有量から求めた全薬剤量との比を図3に示した。
化合物36、化合物37をそれぞれPBS(リン酸緩衝生理食塩水;pH7.1)に1mg/mlの濃度で溶解し、37℃にてインキュベートした。該高分子結合体より放出された各薬剤を、HPLCにて分析し標準曲線を用いて定量した。定量値と高分子結合体の薬剤含有量から求めた全薬剤量との比を図4に示した。
マウス皮下で継代しているマウス大腸癌Colon26を約2mm角のブロックにし、套管針を用いて雌性CDF1マウスの背側部皮下に移植した。腫瘍移植後8日目から本発明の高分子結合体(化合物22)又は対照薬(コンブレタスタチンA4リン酸エステル;CA4P、PEG-Glu-CA4又はPEG-Asp-CA4)を、各々コンブレタスタチンA4換算で体重あたり同量をマウス尾静脈内に単回投与した。各化合物は5%ブドウ糖溶液で溶解して使用した。
コンブレタスタチン類の副作用として心筋障害が知られていることから、心筋や神経に多量に含まれる酵素で障害を受けると血液中に放出されるクレアチニンホスホキナーゼ(CPK)の力価推移を観測し、本発明の化合物の副作用の程度を公知化合物と比較した。
マウス皮下で継代しているマウス大腸癌Colon26を約2mm角のブロックにし、套管針を用いて雌性CDF1マウスの背側部皮下に移植した。腫瘍移植後8日目から本発明の高分子結合体(化合物30)又は対照薬(ドセタキセル;DTX又はPEG-Asp-DTX)を、各々ドセタキセル換算で体重当たり同量をマウス尾静脈内に単回投与した。ドセタキセルは無水エタノールとクレモホール(シグマ社製)に溶解し、使用時に生理食塩液で希釈して用いた。他の化合物は5%ブドウ糖注射液で溶解し用いた。投与後、腫瘍の長径(Lmm)及び短径(Wmm)をノギスで計測し、腫瘍体積を(LxW2)/2により計算し、無処置群(コントロール)の腫瘍体積に対する相対腫瘍体積比として表3に示した。
Claims (25)
- ポリエチレングリコール構造部分と2以上のカルボキシ基を有するポリマーとのブロック共重合体の側鎖カルボキシ基のうちの少なくともひとつに、一般式(I)あるいは一般式(II)
- 2以上のカルボキシ基を有するポリマーがポリアミノ酸又はその誘導体である請求項1に記載の生理活性物質の高分子結合体。
- ポリアミノ酸がポリグルタミン酸である請求項2に記載の生理活性物質の高分子結合体。
- 生理活性物質の高分子結合体が一般式(III)
R4は一般式(I)あるいは一般式(II)
R5は一般式(IV)あるいは一般式(V)
R6は一般式(VI)
R7は(C1~C30)アルコキシ基、(C1~C30)アラルキルオキシ基、(C1~C30)アルキルアミノ基、ジ(C1~C30)アルキルアミノ基、カルボキシ基が保護されたアミノ酸及びNR12CONHR13からなる群から選ばれる置換基を示し、R12、R13は同一でも異なっていてもよく(C3~C6)環状アルキル基若しくは三級アミノ基で置換されていてもよい(C1~C5)アルキル基を示し、bは5~11500の整数を示し、iは1~200の整数を示し、j、k、m、nは各々0~200の整数を示し、且つi+j+k+m+nは2~200の整数を示す]
で表される化合物である請求項1~3のいずれか一項に記載の生理活性物質の高分子結合体。 - R1が(C1~C3)アルキル基であり、R2が(C2~C6)アルキレン基であり、R3が(C1~C3)アシル基であり、bが100~300の整数であり、iが1~90の整数を示し、j、k、m、nが各々0~90の整数を示し、且つi+j+k+m+nは6~90の整数である請求項4に記載の生理活性物質の高分子結合体。
- R1がメチル基、R2がトリメチレン基、R3がアセチル基、R4、R5及びR6におけるR8、R9が共に水素原子であり、CX-CYがCH-CHである請求項4又は5に記載の生理活性物質の高分子結合体。
- 前記ひとつ以上の水酸基を有する生理活性物質が抗癌剤である請求項1~6のいずれか一項に記載の生理活性物質の高分子結合体。
- 抗癌剤がタキサン類である請求項7に記載の生理活性物質の高分子結合体。
- タキサン類がパクリタキセル又はドセタキセルである請求項8に記載の生理活性物質の高分子結合体。
- 抗癌剤がポドフィロトキシン類である請求項7に記載の生理活性物質の高分子結合体。
- ポドフィロトキシン類がポドフィロトキシン、エトポシド又はテニポシドである請求項10に記載の生理活性物質の高分子結合体。
- 抗癌剤がコンブレタスタチン類である請求項7に記載の生理活性物質の高分子結合体。
- コンブレタスタチン類がコンブレタスタチンA1又はコンブレタスタチンA4である請求項12に記載の生理活性物質の高分子結合体。
- 抗癌剤が核酸系抗癌剤である請求項7に記載の生理活性物質の高分子結合体。
- 核酸系抗癌剤がゲムシタビン、カペシタビン、ドキシフルリジン、シタラビン、又は3’-エチニルシチジンである請求項14に記載の生理活性物質の高分子結合体。
- 抗癌剤がカンプトテシン又はその類縁体である請求項7に記載の生理活性物質の高分子結合体。
- 抗癌剤がドキソルビシン、アムルビシン又はアクラシノマイシンである請求項7に記載の生理活性物質の高分子結合体。
- 前記ひとつ以上の水酸基を有する生理活性物質が抗炎症剤である請求項1~6のいずれか一項に記載の生理活性物質の高分子結合体。
- 抗炎症剤がステロイド系抗炎症剤である請求項18に記載の生理活性物質の高分子結合体。
- 前記ひとつ以上の水酸基を有する生理活性物質が鎮痛剤、育毛剤又は心筋梗塞サイズ縮小効果による心筋保護剤である請求項1~6のいずれか一項に記載の生理活性物質の高分子結合体。
- 鎮痛剤、育毛剤又は心筋梗塞サイズ縮小効果による心筋保護剤がアデノシンである請求項20記載の生理活性物質の高分子結合体。
- 水中でミセルを形成することを特徴とする請求項1~21のいずれか一項に記載の生理活性物質の高分子結合体。
- 請求項1~22のいずれか一項に記載の生理活性物質の高分子結合体を有効成分とする医薬品。
- 請求項7~17のいずれか一項に記載の生理活性物質の高分子結合体を有効成分とする抗癌剤。
- 請求項18又は19に記載の生理活性物質の高分子結合体を有効成分とする抗炎症剤。
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10774932.7A EP2431403B1 (en) | 2009-05-15 | 2010-05-12 | Polymer conjugate of bioactive substance having hydroxy group |
US13/319,175 US8808749B2 (en) | 2009-05-15 | 2010-05-12 | Polymer conjugate of bioactive substance having hydroxy group |
CN201080021960.6A CN102421827B (zh) | 2009-05-15 | 2010-05-12 | 具有羟基的生理活性物质的高分子结合体 |
JP2011513356A JP5544357B2 (ja) | 2009-05-15 | 2010-05-12 | 水酸基を有する生理活性物質の高分子結合体 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009-118365 | 2009-05-15 | ||
JP2009118365 | 2009-05-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2010131675A1 true WO2010131675A1 (ja) | 2010-11-18 |
Family
ID=43085048
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2010/058034 WO2010131675A1 (ja) | 2009-05-15 | 2010-05-12 | 水酸基を有する生理活性物質の高分子結合体 |
Country Status (5)
Country | Link |
---|---|
US (1) | US8808749B2 (ja) |
EP (1) | EP2431403B1 (ja) |
JP (1) | JP5544357B2 (ja) |
CN (1) | CN102421827B (ja) |
WO (1) | WO2010131675A1 (ja) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012067138A1 (ja) * | 2010-11-17 | 2012-05-24 | 日本化薬株式会社 | 新規なシチジン系代謝拮抗剤の高分子誘導体 |
US8703878B2 (en) | 2007-09-28 | 2014-04-22 | Nippon Kayaku Kabushiki Kaisha | High-molecular weight conjugate of steroids |
WO2014073447A1 (ja) | 2012-11-08 | 2014-05-15 | 日本化薬株式会社 | カンプトテシン類と抗癌効果増強剤の結合した高分子化合物及びその用途 |
US8920788B2 (en) | 2008-03-18 | 2014-12-30 | Nippon Kayaku Kabushiki Kaisha | High-molecular weight conjugate of physiologically active substances |
US8940332B2 (en) | 2006-05-18 | 2015-01-27 | Nippon Kayaku Kabushiki Kaisha | High-molecular weight conjugate of podophyllotoxins |
US9149540B2 (en) | 2008-05-08 | 2015-10-06 | Nippon Kayaku Kabushiki Kaisha | Polymer conjugate of folic acid or folic acid derivative |
US9346923B2 (en) | 2011-09-11 | 2016-05-24 | Nippon Kayaku Kabushiki Kaisha | Method for manufacturing block copolymer |
US9434822B2 (en) | 2004-09-22 | 2016-09-06 | Nippon Kayaku Kabushiki Kaisha | Block copolymer, micelle preparation, and anticancer agent containing the same as active ingredient |
WO2017119272A1 (ja) * | 2016-01-08 | 2017-07-13 | 日本化薬株式会社 | マクロライド系免疫抑制剤の高分子誘導体 |
WO2017170845A1 (ja) * | 2016-03-30 | 2017-10-05 | ナノキャリア株式会社 | 薬物複合化ブロック共重合体、ブロック共重合体、および薬物複合化ブロック共重合体の製造方法 |
US10946028B2 (en) | 2015-12-22 | 2021-03-16 | Nippon Kayaku Kabushiki Kaisha | Polymer conjugate of sulfoxide derivative-coordinated platinum(II) complex |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2324701C2 (ru) * | 2003-03-20 | 2008-05-20 | Ниппон Каяку Кабусики Кайся | Мицеллярный препарат, содержащий малорастворимый в воде противораковый агент, содержащее его противораковое средство и новый блок-сополимер |
KR20080106254A (ko) * | 2006-03-28 | 2008-12-04 | 니폰 가야꾸 가부시끼가이샤 | 탁산류의 고분자 결합체 |
JP5548364B2 (ja) * | 2006-10-03 | 2014-07-16 | 日本化薬株式会社 | レゾルシノール誘導体の高分子結合体 |
WO2008056596A1 (en) * | 2006-11-06 | 2008-05-15 | Nippon Kayaku Kabushiki Kaisha | Polymeric derivative of nucleic acid metabolic antagonist |
CN107249560A (zh) * | 2015-02-27 | 2017-10-13 | 那野伽利阿株式会社 | 高分子处理剂 |
US20180085333A1 (en) * | 2015-04-16 | 2018-03-29 | Peter Truog | 4-phenylbutyric acid derivatives |
WO2017086235A1 (ja) * | 2015-11-18 | 2017-05-26 | 日本化薬株式会社 | マクロライド系免疫抑制剤の高分子誘導体 |
CN105963707A (zh) * | 2016-05-31 | 2016-09-28 | 中国科学院长春应用化学研究所 | 一种高分子ca4键合药及其制备方法 |
CN106117561B (zh) * | 2016-06-27 | 2020-03-13 | 中国科学院长春应用化学研究所 | 一种吉西他滨衍生物及其制备方法 |
DE102017007671A1 (de) * | 2017-08-14 | 2019-02-14 | Universität Konstanz | Multifunktionelle Blockcopolymere zur Auflösung von atherosklerotischen Plaques |
Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS63502037A (ja) * | 1985-12-19 | 1988-08-11 | バテル メモリアル インステイチユ−ト | 生物分解性合成ポリペプチド及びその治療用途 |
JPH08507558A (ja) * | 1993-03-06 | 1996-08-13 | ビーエーエスエフ アクチエンゲゼルシャフト | ポリアスパラギン酸イミドとアミノ酸からの反応生成物の製法ならびに該生成物の使用 |
JP2694923B2 (ja) | 1995-08-21 | 1997-12-24 | 科学技術振興事業団 | 水溶性高分子化医薬製剤 |
JP2002069184A (ja) * | 2000-06-12 | 2002-03-08 | Mitsui Chemicals Inc | 重合体及びその製造方法 |
WO2004039869A1 (ja) | 2002-10-31 | 2004-05-13 | Nippon Kayaku Kabushiki Kaisha | カンプトテシン類の高分子誘導体 |
WO2006120914A1 (ja) | 2005-05-11 | 2006-11-16 | Nippon Kayaku Kabushiki Kaisha | シチジン系代謝拮抗剤の高分子誘導体 |
JP2007511586A (ja) * | 2003-11-21 | 2007-05-10 | フラメル・テクノロジー | 有効成分の放出の延長のための薬学的調製物およびその適用、特に治療学的適用 |
WO2007111211A1 (ja) | 2006-03-28 | 2007-10-04 | Nippon Kayaku Kabushiki Kaisha | タキサン類の高分子結合体 |
WO2007135910A1 (ja) | 2006-05-18 | 2007-11-29 | Nippon Kayaku Kabushiki Kaisha | ポドフィロトキシン類の高分子結合体 |
WO2008010463A1 (fr) | 2006-07-19 | 2008-01-24 | Nippon Kayaku Kabushiki Kaisha | Conjugué polymère d'une combrétastatine |
WO2008056654A1 (en) * | 2006-11-08 | 2008-05-15 | Nippon Kayaku Kabushiki Kaisha | Polymeric derivative of nucleic acid metabolic antagonist |
Family Cites Families (96)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1467587A (en) | 1974-07-11 | 1977-03-16 | Nestle Sa | Preparation of an asparagine or a glutamine |
GB8500209D0 (en) | 1985-01-04 | 1985-02-13 | Ceskoslovenska Akademie Ved | Synthetic polymeric drugs |
JPS6296088A (ja) | 1985-10-22 | 1987-05-02 | Kanebo Ltd | 抗腫瘍性物質の製法 |
US4734512A (en) | 1985-12-05 | 1988-03-29 | Bristol-Myers Company | Intermediates for the production of podophyllotoxin and related compounds and processes for the preparation and use thereof |
JPS6310789A (ja) | 1986-07-01 | 1988-01-18 | Nippon Kayaku Co Ltd | 新規ポドフイロトキシン誘導体 |
JPS6323884A (ja) | 1986-07-17 | 1988-02-01 | Nippon Kayaku Co Ltd | 新規ポドフイロトキシン誘導体 |
JPS6461422A (en) | 1987-09-02 | 1989-03-08 | Nippon Kayaku Kk | Water-soluble polymeric carcinostatic agent |
JPS6461423A (en) | 1987-09-02 | 1989-03-08 | Nippon Kayaku Kk | Water-soluble polymeric carcinostatic agent |
US5182203A (en) | 1989-03-29 | 1993-01-26 | E. I. Du Pont De Nemours And Company | Bifunctional compounds useful in catalyzed reporter deposition |
JP2517760B2 (ja) | 1989-05-11 | 1996-07-24 | 新技術事業団 | 水溶性高分子化医薬製剤 |
US5543390A (en) | 1990-11-01 | 1996-08-06 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University | Covalent microparticle-drug conjugates for biological targeting |
JP3310000B2 (ja) | 1990-11-07 | 2002-07-29 | 靖久 桜井 | 水溶性高分子抗癌剤及び薬物担持用担体 |
WO1993024476A1 (en) | 1992-06-04 | 1993-12-09 | Clover Consolidated, Limited | Water-soluble polymeric carriers for drug delivery |
KR940003548U (ko) | 1992-08-14 | 1994-02-21 | 김형술 | 세탁물 건조기 |
US5614549A (en) | 1992-08-21 | 1997-03-25 | Enzon, Inc. | High molecular weight polymer-based prodrugs |
JP3268913B2 (ja) | 1992-10-27 | 2002-03-25 | 日本化薬株式会社 | 高分子担体 |
FR2698543B1 (fr) | 1992-12-02 | 1994-12-30 | Rhone Poulenc Rorer Sa | Nouvelles compositions à base de taxoides. |
US5985548A (en) | 1993-02-04 | 1999-11-16 | E. I. Du Pont De Nemours And Company | Amplification of assay reporters by nucleic acid replication |
US5840900A (en) | 1993-10-20 | 1998-11-24 | Enzon, Inc. | High molecular weight polymer-based prodrugs |
US5880131A (en) | 1993-10-20 | 1999-03-09 | Enzon, Inc. | High molecular weight polymer-based prodrugs |
US5571889A (en) | 1994-05-30 | 1996-11-05 | Mitsui Toatsu Chemicals, Inc. | Polymer containing monomer units of chemically modified polyaspartic acids or their salts and process for preparing the same |
US5552517A (en) | 1995-03-03 | 1996-09-03 | Monsanto Company | Production of polysuccinimide in an organic medium |
SG50747A1 (en) | 1995-08-02 | 1998-07-20 | Tanabe Seiyaku Co | Comptothecin derivatives |
CN1304058C (zh) | 1996-03-12 | 2007-03-14 | Pg-Txl有限公司 | 水溶性紫杉醇产品 |
ATE310538T1 (de) * | 1996-04-15 | 2005-12-15 | Asahi Chemical Ind | Arzneimittelkomplexe enthaltend taxan- verbindungen oder steroiden |
US5877205A (en) | 1996-06-28 | 1999-03-02 | Board Of Regents, The University Of Texas System | Parenteral paclitaxel in a stable non-toxic formulation |
KR100476247B1 (ko) | 1996-07-15 | 2005-03-10 | 가부시키가이샤 야쿠루트 혼샤 | 탁산 유도체 및 그를 함유하는 의약 |
JP2000516948A (ja) | 1996-08-26 | 2000-12-19 | トランジェーヌ、ソシエテ、アノニム | カチオン性脂質―核酸複合体 |
GB9625895D0 (en) | 1996-12-13 | 1997-01-29 | Riley Patrick A | Novel compound useful as therapeutic agents and assay reagents |
ES2197265T3 (es) | 1997-05-09 | 2004-01-01 | Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts | Conjugado que comprende un anatagonista de aacido folico y un portador. |
WO1999030727A1 (en) | 1997-12-17 | 1999-06-24 | Enzon, Inc. | Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents |
US6824766B2 (en) | 1998-04-17 | 2004-11-30 | Enzon, Inc. | Biodegradable high molecular weight polymeric linkers and their conjugates |
US6153655A (en) | 1998-04-17 | 2000-11-28 | Enzon, Inc. | Terminally-branched polymeric linkers and polymeric conjugates containing the same |
IN191203B (ja) | 1999-02-17 | 2003-10-04 | Amarnath Prof Maitra | |
US6207832B1 (en) | 1999-04-09 | 2001-03-27 | University Of Pittsburgh | Camptothecin analogs and methods of preparation thereof |
US20010041189A1 (en) | 1999-04-13 | 2001-11-15 | Jingya Xu | Poly(dipeptide) as a drug carrier |
US6713454B1 (en) | 1999-09-13 | 2004-03-30 | Nobex Corporation | Prodrugs of etoposide and etoposide analogs |
US6380405B1 (en) | 1999-09-13 | 2002-04-30 | Nobex Corporation | Taxane prodrugs |
AU783104B2 (en) | 1999-09-14 | 2005-09-22 | Tepha, Inc. | Therapeutic uses of polymers and oligomers comprising gamma-hydroxybutyrate |
US6376470B1 (en) | 1999-09-23 | 2002-04-23 | Enzon, Inc. | Polymer conjugates of ara-C and ara-C derivatives |
EP1225917A2 (en) | 1999-10-12 | 2002-07-31 | Cell Therapeutics, Inc. | Manufacture of polyglutamate-therapeutic agent conjugates |
US20030054977A1 (en) | 1999-10-12 | 2003-03-20 | Cell Therapeutics, Inc. | Manufacture of polyglutamate-therapeutic agent conjugates |
JP3523821B2 (ja) | 2000-02-09 | 2004-04-26 | ナノキャリア株式会社 | 薬物が封入されたポリマーミセルの製造方法および該ポリマーミセル組成物 |
WO2001064198A2 (en) | 2000-02-29 | 2001-09-07 | Janssen Pharmaceutica N.V. | Farnesyl protein transferase inhibitor combinations with anti-tumor podophyllotoxin derivatives |
PL358335A1 (en) | 2000-03-17 | 2004-08-09 | Cell Therapeutics, Inc. | Polyglutamic acid-camptothecin conjugates and methods of preparation |
US20020161062A1 (en) | 2001-11-06 | 2002-10-31 | Biermann Paul J. | Structure including a plurality of cells of cured resinous material, method of forming the structure and apparatus for forming the structure |
WO2001092584A1 (en) | 2000-06-02 | 2001-12-06 | Eidgenossische Technische Hochschule Zurich | Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds |
US6743937B2 (en) | 2000-07-17 | 2004-06-01 | Oxigene, Inc. | Efficient method of synthesizing combretastatin A-4 prodrugs |
US20020099013A1 (en) | 2000-11-14 | 2002-07-25 | Thomas Piccariello | Active agent delivery systems and methods for protecting and administering active agents |
JP2005508832A (ja) | 2001-02-16 | 2005-04-07 | セルゲイト, インコーポレイテッド | 間隔を開けてアルギニン部分を含むトランスポーター |
EP1362053B1 (en) | 2001-02-20 | 2007-11-14 | Enzon, Inc. | Terminally-branched polymeric linkers and polymeric conjugates containing the same |
ATE378071T1 (de) | 2001-02-20 | 2007-11-15 | Enzon Inc | Endgruppenverzweigte polymere verbindungen und diese enthaltende polymere konjugate |
ES2343679T3 (es) | 2001-06-20 | 2010-08-06 | Nippon Kayaku Kabushiki Kaisha | Copolimeros de bloques con bajo contenido de impurezas; vehiculo polimerico; preparaciones farmaceuticas en forma polimerica y procedimiento para la preparacion del mismo. |
CA2463902A1 (en) | 2001-10-26 | 2003-05-01 | Oxigene, Inc. | Functionalized stilbene derivatives as improved vascular targeting agents |
AU2002356301A1 (en) | 2001-12-21 | 2003-07-15 | Cancer Research Technology Ltd. | 3,4-diarylpyrazoles and their use in the therapy of cancer |
KR101003622B1 (ko) | 2002-03-01 | 2010-12-24 | 더 어드미니스트레이터 오브 더 튜레인 에듀케이셔널 펀드 | 치료제 또는 세포독성제와 생물학적 활성 펩티드의컨쥬게이트 |
CN100475269C (zh) | 2002-03-05 | 2009-04-08 | 北京键凯科技有限公司 | 亲水性聚合物-谷氨酸寡肽与药物分子的结合物、包含该结合物的组合物及用途 |
JPWO2003080077A1 (ja) | 2002-03-26 | 2005-07-21 | 萬有製薬株式会社 | 抗腫瘍性インドロピロロカルバゾール誘導体と他の抗がん剤との併用 |
US6596757B1 (en) | 2002-05-14 | 2003-07-22 | Immunogen Inc. | Cytotoxic agents comprising polyethylene glycol-containing taxanes and their therapeutic use |
JP2003342168A (ja) | 2002-05-24 | 2003-12-03 | Nano Career Kk | 注射用薬物含有ポリマーミセル製剤の製造方法 |
JP2003342167A (ja) | 2002-05-24 | 2003-12-03 | Nano Career Kk | カンプトテシン誘導体の製剤およびその調製方法 |
JP4270485B2 (ja) | 2002-05-28 | 2009-06-03 | 第一三共株式会社 | タキサン類の還元方法 |
JP2004010479A (ja) | 2002-06-03 | 2004-01-15 | Japan Science & Technology Corp | ブロック共重合体とアンスラサイクリン系抗癌剤を含む新規固型製剤及びその製造法 |
GB0228417D0 (en) | 2002-12-05 | 2003-01-08 | Cancer Rec Tech Ltd | Pyrazole compounds |
GB0229618D0 (en) | 2002-12-19 | 2003-01-22 | Cancer Rec Tech Ltd | Pyrazole compounds |
US7169892B2 (en) | 2003-01-10 | 2007-01-30 | Astellas Pharma Inc. | Lipid-peptide-polymer conjugates for long blood circulation and tumor specific drug delivery systems |
CN1771235B (zh) | 2003-02-11 | 2010-04-28 | 弗奈利斯(剑桥)有限公司 | 异噁唑化合物 |
RU2324701C2 (ru) | 2003-03-20 | 2008-05-20 | Ниппон Каяку Кабусики Кайся | Мицеллярный препарат, содержащий малорастворимый в воде противораковый агент, содержащее его противораковое средство и новый блок-сополимер |
CA2518223A1 (en) | 2003-03-26 | 2004-10-07 | Ltt Bio-Pharma Co., Ltd. | Intravenous nanoparticles for targeting drug delivery and sustained drug release |
GB0309637D0 (en) | 2003-04-28 | 2003-06-04 | Cancer Rec Tech Ltd | Pyrazole compounds |
GB0315111D0 (en) | 2003-06-27 | 2003-07-30 | Cancer Rec Tech Ltd | Substituted 5-membered ring compounds and their use |
WO2005018674A1 (ja) | 2003-08-22 | 2005-03-03 | Kyowa Hakko Kogyo Co., Ltd. | イムノグロブリン遺伝子の転座を伴う疾患の治療薬 |
CA2542834C (en) | 2003-10-21 | 2012-04-24 | Igf Oncology, Llc | Conjugates or co-administration of igf-1 receptor ligands with anti-cancer chemotherapeutic agents |
US7176185B2 (en) | 2003-11-25 | 2007-02-13 | Tsrl, Inc. | Short peptide carrier system for cellular delivery of agent |
KR101142583B1 (ko) | 2004-01-07 | 2012-05-11 | 세이가가쿠 고교 가부시키가이샤 | 히알루론산 유도체 및 그것을 포함하는 약제 |
ES2410591T3 (es) | 2004-09-22 | 2013-07-02 | Nippon Kayaku Kabushiki Kaisha | Nuevo copolímero en bloque, preparación micelar y agente antineoplásico que lo contiene como principio activo |
DK1831440T3 (da) | 2004-11-16 | 2010-11-08 | Hyperion Catalysis Int | Fremgangsmåder til fremstilling af katalysatorer understøttet på carbonnanorørnetværk |
RS52642B (en) | 2004-11-18 | 2013-06-28 | Synta Pharmaceuticals Corp. | TRIAZOLE COMPOUNDS MODULATING HSP90 ACTIVITY |
US8399464B2 (en) | 2005-03-09 | 2013-03-19 | Nippon Kayaku Kabushiki Kaisha | HSP90 inhibitor |
JPWO2006095668A1 (ja) | 2005-03-09 | 2008-08-14 | 東レ株式会社 | 微粒子および医薬品組成物 |
CA2598899A1 (en) | 2005-03-09 | 2006-09-14 | Nippon Kayaku Kabushiki Kaisha | Novel hsp90 inhibitor |
JP2008137894A (ja) | 2005-03-22 | 2008-06-19 | Nippon Kayaku Co Ltd | 新規なアセチレン誘導体 |
WO2006115293A1 (ja) | 2005-04-22 | 2006-11-02 | The University Of Tokyo | pH応答性高分子ミセルの調製に用いる新規ブロック共重合体及びその製造法 |
WO2006120915A1 (ja) | 2005-05-12 | 2006-11-16 | Nipro Corporation | 循環障害改善剤 |
JP2009504783A (ja) | 2005-08-19 | 2009-02-05 | エンドサイト,インコーポレイテッド | ビンカアルカロイド、類似体および誘導体のリガンド結合体 |
CN1800238A (zh) * | 2005-12-05 | 2006-07-12 | 中国科学院长春应用化学研究所 | 有生物功能的脂肪族聚酯—聚氨基酸共聚物及合成方法 |
JP2007182407A (ja) | 2006-01-10 | 2007-07-19 | Medgel Corp | 徐放性ハイドロゲル製剤 |
JP2007191643A (ja) | 2006-01-20 | 2007-08-02 | Mitsui Chemicals Inc | 生体への定着性が付与されたポリアミノ酸誘導体 |
JP5548364B2 (ja) | 2006-10-03 | 2014-07-16 | 日本化薬株式会社 | レゾルシノール誘導体の高分子結合体 |
WO2008056596A1 (en) | 2006-11-06 | 2008-05-15 | Nippon Kayaku Kabushiki Kaisha | Polymeric derivative of nucleic acid metabolic antagonist |
US20080181852A1 (en) * | 2007-01-29 | 2008-07-31 | Nitto Denko Corporation | Multi-functional Drug Carriers |
CN101808651B (zh) | 2007-09-28 | 2013-03-27 | 日本化药株式会社 | 类固醇类的高分子结合物 |
WO2009116509A1 (ja) | 2008-03-18 | 2009-09-24 | 日本化薬株式会社 | 生理活性物質の高分子結合体 |
US9149540B2 (en) | 2008-05-08 | 2015-10-06 | Nippon Kayaku Kabushiki Kaisha | Polymer conjugate of folic acid or folic acid derivative |
DK2287230T3 (da) | 2008-05-23 | 2012-12-10 | Nanocarrier Co Ltd | Docetaxel polymer derivative, method for producing same and use of same |
JP5856069B2 (ja) | 2010-11-17 | 2016-02-09 | 日本化薬株式会社 | 新規なシチジン系代謝拮抗剤の高分子誘導体 |
-
2010
- 2010-05-12 JP JP2011513356A patent/JP5544357B2/ja not_active Expired - Fee Related
- 2010-05-12 US US13/319,175 patent/US8808749B2/en not_active Expired - Fee Related
- 2010-05-12 EP EP10774932.7A patent/EP2431403B1/en not_active Not-in-force
- 2010-05-12 WO PCT/JP2010/058034 patent/WO2010131675A1/ja active Application Filing
- 2010-05-12 CN CN201080021960.6A patent/CN102421827B/zh not_active Expired - Fee Related
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS63502037A (ja) * | 1985-12-19 | 1988-08-11 | バテル メモリアル インステイチユ−ト | 生物分解性合成ポリペプチド及びその治療用途 |
JPH08507558A (ja) * | 1993-03-06 | 1996-08-13 | ビーエーエスエフ アクチエンゲゼルシャフト | ポリアスパラギン酸イミドとアミノ酸からの反応生成物の製法ならびに該生成物の使用 |
JP2694923B2 (ja) | 1995-08-21 | 1997-12-24 | 科学技術振興事業団 | 水溶性高分子化医薬製剤 |
JP2002069184A (ja) * | 2000-06-12 | 2002-03-08 | Mitsui Chemicals Inc | 重合体及びその製造方法 |
WO2004039869A1 (ja) | 2002-10-31 | 2004-05-13 | Nippon Kayaku Kabushiki Kaisha | カンプトテシン類の高分子誘導体 |
JP2007511586A (ja) * | 2003-11-21 | 2007-05-10 | フラメル・テクノロジー | 有効成分の放出の延長のための薬学的調製物およびその適用、特に治療学的適用 |
WO2006120914A1 (ja) | 2005-05-11 | 2006-11-16 | Nippon Kayaku Kabushiki Kaisha | シチジン系代謝拮抗剤の高分子誘導体 |
WO2007111211A1 (ja) | 2006-03-28 | 2007-10-04 | Nippon Kayaku Kabushiki Kaisha | タキサン類の高分子結合体 |
WO2007135910A1 (ja) | 2006-05-18 | 2007-11-29 | Nippon Kayaku Kabushiki Kaisha | ポドフィロトキシン類の高分子結合体 |
WO2008010463A1 (fr) | 2006-07-19 | 2008-01-24 | Nippon Kayaku Kabushiki Kaisha | Conjugué polymère d'une combrétastatine |
WO2008056654A1 (en) * | 2006-11-08 | 2008-05-15 | Nippon Kayaku Kabushiki Kaisha | Polymeric derivative of nucleic acid metabolic antagonist |
Non-Patent Citations (2)
Title |
---|
J. MED. CHEM., vol. 38, 1995, pages 1666 - 1672 |
See also references of EP2431403A4 * |
Cited By (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9434822B2 (en) | 2004-09-22 | 2016-09-06 | Nippon Kayaku Kabushiki Kaisha | Block copolymer, micelle preparation, and anticancer agent containing the same as active ingredient |
US8940332B2 (en) | 2006-05-18 | 2015-01-27 | Nippon Kayaku Kabushiki Kaisha | High-molecular weight conjugate of podophyllotoxins |
US8703878B2 (en) | 2007-09-28 | 2014-04-22 | Nippon Kayaku Kabushiki Kaisha | High-molecular weight conjugate of steroids |
USRE46190E1 (en) | 2007-09-28 | 2016-11-01 | Nippon Kayaku Kabushiki Kaisha | High-molecular weight conjugate of steroids |
US8920788B2 (en) | 2008-03-18 | 2014-12-30 | Nippon Kayaku Kabushiki Kaisha | High-molecular weight conjugate of physiologically active substances |
US9149540B2 (en) | 2008-05-08 | 2015-10-06 | Nippon Kayaku Kabushiki Kaisha | Polymer conjugate of folic acid or folic acid derivative |
EP2641605A1 (en) * | 2010-11-17 | 2013-09-25 | Nippon Kayaku Kabushiki Kaisha | Novel polymer derivative of cytidine metabolism antagonist |
EP2641605A4 (en) * | 2010-11-17 | 2015-04-22 | Nippon Kayaku Kk | NEW CYTIDINE METABOLISM ANTAGONIST POLYMER DERIVATIVE |
US9018323B2 (en) | 2010-11-17 | 2015-04-28 | Nippon Kayaku Kabushiki Kaisha | Polymer derivative of cytidine metabolic antagonist |
JP5856069B2 (ja) * | 2010-11-17 | 2016-02-09 | 日本化薬株式会社 | 新規なシチジン系代謝拮抗剤の高分子誘導体 |
WO2012067138A1 (ja) * | 2010-11-17 | 2012-05-24 | 日本化薬株式会社 | 新規なシチジン系代謝拮抗剤の高分子誘導体 |
US9346923B2 (en) | 2011-09-11 | 2016-05-24 | Nippon Kayaku Kabushiki Kaisha | Method for manufacturing block copolymer |
JPWO2014073447A1 (ja) * | 2012-11-08 | 2016-09-08 | 日本化薬株式会社 | カンプトテシン類と抗癌効果増強剤の結合した高分子化合物及びその用途 |
WO2014073447A1 (ja) | 2012-11-08 | 2014-05-15 | 日本化薬株式会社 | カンプトテシン類と抗癌効果増強剤の結合した高分子化合物及びその用途 |
US9855261B2 (en) | 2012-11-08 | 2018-01-02 | Nippon Kayaku Kabushiki Kaisha | Polymeric compound having camptothecin compound and anti-cancer effect enhancer bound thereto, and use of same |
US10946028B2 (en) | 2015-12-22 | 2021-03-16 | Nippon Kayaku Kabushiki Kaisha | Polymer conjugate of sulfoxide derivative-coordinated platinum(II) complex |
WO2017119272A1 (ja) * | 2016-01-08 | 2017-07-13 | 日本化薬株式会社 | マクロライド系免疫抑制剤の高分子誘導体 |
JPWO2017119272A1 (ja) * | 2016-01-08 | 2018-11-01 | 日本化薬株式会社 | マクロライド系免疫抑制剤の高分子誘導体 |
US10945997B2 (en) | 2016-01-08 | 2021-03-16 | Nippon Kayaku Kabushiki Kaisha | Polymer derivative of macrolide immunosuppressant |
WO2017170845A1 (ja) * | 2016-03-30 | 2017-10-05 | ナノキャリア株式会社 | 薬物複合化ブロック共重合体、ブロック共重合体、および薬物複合化ブロック共重合体の製造方法 |
Also Published As
Publication number | Publication date |
---|---|
CN102421827A (zh) | 2012-04-18 |
CN102421827B (zh) | 2014-07-30 |
EP2431403A1 (en) | 2012-03-21 |
US20120116051A1 (en) | 2012-05-10 |
EP2431403B1 (en) | 2016-09-28 |
EP2431403A4 (en) | 2014-12-31 |
US8808749B2 (en) | 2014-08-19 |
JP5544357B2 (ja) | 2014-07-09 |
JPWO2010131675A1 (ja) | 2012-11-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5544357B2 (ja) | 水酸基を有する生理活性物質の高分子結合体 | |
JP5856069B2 (ja) | 新規なシチジン系代謝拮抗剤の高分子誘導体 | |
US8323669B2 (en) | Polymer conjugate of taxane | |
EP2258397B1 (en) | Polymer conjugate of physiologically active substance | |
CA2502870C (en) | High-molecular weight derivatives of camptothecins | |
JP5349318B2 (ja) | ステロイド類の高分子結合体 | |
JP5181347B2 (ja) | ポドフィロトキシン類の高分子結合体 | |
EP2042195A1 (en) | Polymer conjugate of combretastatin | |
WO2014073447A1 (ja) | カンプトテシン類と抗癌効果増強剤の結合した高分子化合物及びその用途 | |
WO2016093352A1 (ja) | 核酸代謝拮抗剤が結合した多分岐化合物 | |
WO2017119272A1 (ja) | マクロライド系免疫抑制剤の高分子誘導体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201080021960.6 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10774932 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011513356 Country of ref document: JP |
|
REEP | Request for entry into the european phase |
Ref document number: 2010774932 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010774932 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13319175 Country of ref document: US |